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Thesis Abstract 
3,4-methylenedioxymehtamphetamine (MDMA, ‘ecstasy’) is an illegal stimulant drug that can 
produce life-threatening hyperthermia following consumption in humans. Administration of 
MDMA also produces similar effects in experimental animals and it can lead to death usually 
through multi-organ failure, and vasogenic brain oedema. Despite the danger acute MDMA-
induced hyperthermia poses, current treatments for these adverse effects in a clinical setting 
are limited and do not address hyperthermia’s central origins. Due to ethical reasons, the 
investigation of these MDMA-induced changes in humans are restricted, therefore animal 
models are relied on to investigate the real-time thermoregulatory effects of MDMA and their 
underlying pharmacological mechanisms. This being considered, it is important to investigate 
MDMAs adverse effects in animals and potential pharmacological therapeutics using 
advantageous techniques in order to effectively relate these findings from animals to humans. 
The aim of this thesis was to develop a novel portable optical fibre temperature sensor for the 
monitoring of brain temperature in awake freely-moving rats, and to use this sensor in 
conjunction with radiotelemetry to investigate the effects of MDMA on thermoregulation and 
its related physiological parameters. We also aimed to investigate the brain hyperthermia-
attenuating effects of the tetracycline antibiotic drug minocycline, as well as its effects on body 
temperature, heart rate, and locomotor activity. 
The first part of this thesis aimed at optimizing a portable optical fibre temperature sensor based 
on rare-earth thermometry for long-term temperature measurements in vivo. Initial in vitro tests 
revealed measurement instabilities in the original configuration and therefore changes were 
made to the optical equipment aimed at increasing its long-term stability. The susceptibility of 
the previous probe to signal bend-loss and breakage during animal movement following 
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MDMA administration was also reduced through numerous physical changes to the sensor 
design. 
The second study aimed to provide proof-of-concept for this portable optical fibre-tip sensor 
capable of recording brain temperature in conscious freely-moving rats. This study was 
successful in demonstrating that accurate and spatially precise brain temperature recordings 
could be performed by the probe while utilising a portable optical setup. These brain 
temperature measurements also showed a good correlation with body temperature recorded 
with radiotelemetry throughout the experiment. 
The third study made further improvements to the probe structure which increased probe 
durability, reusability and ease of use for in vivo experiments. These changes significantly 
increased experimental throughput and reduced time and resource costs associated with probe 
fabrication. Brain temperature measurements made with this probe showed that MDMA (10 
mg/kg) induced a significant hyperthermia in the brains of Sprague-Dawley rats. 
The fourth study looked at the effects of MDMA administered at differing ambient 
temperatures, as well as the hyperthermia attenuating effects of minocycline. Administration 
of MDMA (10 mg/kg) induced both a significant hypothermia and hyperthermia when 
administered at normal, and high ambient temperature respectively, and significantly increased 
heart rate, and locomotor activity irrespective of environmental conditions. Pretreatment with 
minocycline (50 mg/kg) was able to significantly attenuate MDMA-induced brain and body 
hyperthermia at high ambient temperature and reduce MDMA-induced increases in heart rate 
and locomotor activity. 
In conclusion, we have developed and validated an optical fibre point temperature sensor based 
on rare-earth thermometry that accurately records rat brain temperature in vivo. We also 
combined optical fibre brain temperature measurements with body temperature monitoring to 
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investigate the thermoregulatory, and physiological effects of MDMA and minocycline in 
freely-moving rats.  
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Chapter 1 - Research Background 
3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) is an amphetamine derivative drug 
used worldwide in raves and night clubs. MDMA has the tendency to be viewed as a less 
harmful substance when compared to alleged ‘hard’ drugs, such as cocaine and heroin, due to 
its stimulant, and positive mood enhancing effects, in addition to its perceived lack of acute 
side effects. However, in some users, MDMA administration can result in fatality. 
Hyperthermia is the most severe acute consequence of MDMA; however, it is hard to predict 
when this severe and sometimes fatal adverse effect will occur. Fatal case reports of MDMA 
users show varied MDMA plasma concentrations following drug administration (Gowing et 
al., 2002, Caldicott et al., 2003), and animal studies report that there are many contributing 
behavioural, and environmental factors that can exacerbate the hyperthermic response 
(Malberg and Seiden, 1998, Brown and Kiyatkin, 2004, Ridge et al., 2019). The hyperthermic 
response in the brain is the most severe adverse effect of MDMA administration as it can lead 
to deleterious effects in the brain including neuronal cell damage (Kiyatkin, 2010), disruption 
of the blood-brain barrier and brain oedema (Kiyatkin et al., 2007, Kiyatkin and Sharma, 2009, 
Kiyatkin et al., 2014, Kiyatkin et al., 2016), and is likely responsible for the exacerbation of 
monoamine system neurotoxicity (Broening et al., 1995, Malberg and Seiden, 1998, O'Shea et 
al., 2005, Li et al., 2019). Despite the potential dangers that MDMA administration poses, 
emergency room strategies to manage these serious adverse effects are limited. Current 
emergency techniques to counteract MDMA-induced hyperthermia include simple whole body 
cooling, fluid replacement, anaesthesia, and muscle relaxants in extreme cases of hyperpyrexia 
(Hall and Henry, 2006, Grunau et al., 2010). Considering these limited options, there is a 
pressing need for effective pharmacotherapy to treat MDMA-induced hyperthermia in a 
clinical setting. In order to investigate the adverse effects of MDMA, as well as the potential 
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pharmacotherapies for attenuating MDMA-induced hyperthermia, animal models of drug-
induced hyperthermia are essential. However, there are some deficiencies apparent in previous 
animal studies investigating MDMA-induced hyperthermia related to choice of observed 
parameters and methodological approaches to temperature measurement. Until recently, 
MDMA’s effects on brain temperature remained relatively unexplored compared to its effects 
in the body, even though it has since been revealed that the most severe and damaging 
temperature effects of MDMA occur in the brain (Brown and Kiyatkin, 2004, Kiyatkin et al., 
2014). In addition to this, many previous studies relied on rectal or ear temperature 
measurements to record MDMA-induced core temperature change, which have since been 
shown to lead to stress-induced increases in core temperature (Gordon, 1990, Bae et al., 2007). 
Even studies measuring brain temperature have utilised thermocouple electrodes to record 
MDMA-induced brain temperature changes, which while effective, lack the many advantages 
provided by more modern techniques such as optical fibre-based sensing methods (Lee, 2003). 
We therefore decided to develop a new method to examine the thermoregulatory and 
physiological effects of MDMA using an optical fibre brain temperature sensor, and implanted 
telemetry device in freely-moving rats. 
 
The first aim of this project was to develop and validate an optical fibre-based point brain 
temperature sensor suitable for in vivo use outside of a conventional optics laboratory. 
Following this successful proof-of-concept, the second main aim was to investigate the 
thermoregulatory and physiological effects of MDMA, as well as the brain hyperthermia-
attenuating effects of the tetracycline-derivative drug minocycline, previously shown to 
attenuate MDMA-induced increases in core body temperature. The approach involved a 
sequence of in vitro and in vivo optical fibre probe trials to optimise the new method, as well 
as many subsequent sequential improvements before it was reliable for use in MDMA-treated 
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rats. This sensor along with the implanted telemetry devices were then used to investigate the 
thermoregulatory, and physiological effects of MDMA and minocycline in the brain and body 
under differing environmental conditions. 
1.1 Historical origins of 3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) 
MDMA was first synthesised by Merck, a German Pharmaceutical company in 1912 
(Freudenmann et al., 2006). In the 1950’s it was studied by the US army along with other 
mescaline analogues in five animal models, however, this work was not published until much 
later (Hardman et al., 1973). The psychoactive properties of the drug in humans were published 
soon after this (Anderson et al., 1978). MDMA started to be used recreationally throughout the 
1970’s by small numbers of people, however after its classification as a Schedule 1 drug in 
1985 its use increased following its increased publicity (Parrott, 2001). It has since become 
more popular since the 1980’s as a party drug at “rave” or “dance” parties under the name 
“ecstasy”. The name ecstasy often refers to MDMA, a ring substituted amphetamine derivative 
related to the hallucinogenic compound mescaline (Hardman et al., 1973, Kamien et al., 1986) 
through chemical structure, and is closely related to methamphetamine, a psychomotor 
stimulant (Kamien et al., 1986). These compounds contain structural modifications such as 
methoxy group at various positions on the benzene ring and varying lengths and branching of 
the side chain leading to differences in their pharmacological activity (Hardman et al., 1973). 
Although the majority of ecstasy tablets contain MDMA, they can often contain other related 
chemicals (Fig. 1.1) such as 3,4-methelenedioxyamphetamine (MDA), 3,4-
methylenedioxyethamphetamine (MDEA), para-methoxyamphetamine (PMA) as well as other 
types of drugs like ephedrine, salicylates and painkillers (Cole et al., 2002). 
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Figure 1.1: Chemical structures of MDMA and related amphetamine derivatives.  
1.2 Prevalence of MDMA use 
MDMA is a drug commonly used by adolescents and young adults. Published studies report 
that 6.5% of young adults in high school have reported at least one use of the substance 
(Johnston et al., 2007), with its increased use in universities and college campuses well 
documented (Strote et al., 2002). According to Australia’s national drug household survey 
(2016), the most commonly used illegal drugs that were used at least once in the past 12 months 
were cannabis (10.4%), cocaine (2.5%), ecstasy (2.2%) and meth/amphetamines (1.4%) 
(Australian Institute of Health and Welfare, 2017). Historically, Oceania has reported high 
levels of ecstasy use compared to the rest of the world, and more recent reports show that 
estimated past-year prevalence rates for the drug’s use in the region are still among the highest 
in the world (United Nations, 2018). In 2016, increased use of the drug was reported in New 
Zealand, whereas Australia saw the past-year use of the drug among the population aged 14 or 
older fall from 2.5% in 2013, to 2.2% (approximately 400,000) in 2016 (Fig. 1.2) (Australian 
Institute of Health and Welfare, 2017). However, within this same demographic, 11.2% (2.2 
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past 12 months, 7.0% of people in their twenties had recently used ecstasy, and the average age 
of people trying ecstasy for the first time was 21.7 years old (Australian Institute of Health and 
Welfare, 2017).  
 
Figure 1.2: Australian drug-taking behaviours, people aged 14-26, 2001-2016 (%). Derived from Australian 
Institute of Health and Welfare (2017). 
1.3 Effects of MDMA in Humans 
 1.3.1 Desirable effects 
The desirable psychological effects of MDMA are responsible for ecstasy use in humans as 
shown in Table 1. After MDMA administration humans have reported feelings of euphoria, 
increased sense of closeness with others, reduction of negative thoughts, happiness, increased 
energy, calmness, relaxation, as well as heightened perception of senses (Green et al., 2003, 
Baylen and Rosenberg, 2006, Davison and Parrott, 1997). It is used as a recreational drug as it 
is perceived by its users as relatively safe. It is primarily ingested in pill form and thus is not 
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associated with the unpleasant aspects of ‘hard’ intravenous drugs such as heroin. The drug has 
a low potential for dependence and addiction and is not usually associated with aggressive or 











1.3.2 Acute adverse effects 
The recreational use of ecstasy has many adverse side effects. It can cause motor and muscular 
problems like hyperactivity, muscle ache, tension, and jaw clenching as well as complications 
such as elevated blood pressure and heart rate (HR), nausea, chills, sweating and hyperthermia 
(Green et al., 2003, McCann et al., 1996, Davison and Parrott, 1997). Evidence suggests that 
risk of adverse side effects is low (Byard et al., 1998), however the events are unpredictable 
and heavily influenced and exacerbated by a wide range of factors that increase the chance of 
death or morbidity (Gowing et al., 2002, Williamson et al., 1997). Hyperthermia is the major 
adverse effect of acute MDMA toxicity, which can lead to death due to cardiac arrhythmias, 
acute renal failure, rhabdomyolysis, brain oedema and disseminated intravascular coagulation 
(Lyles and Cadet, 2003). Hyperthermia occurs when the body’s thermoregulatory mechanisms 
are overwhelmed by excessive metabolic production of heat, excessive environmental heat, or 






Warm and Friendly 100 
Increased perception of sound 100 
Increased perception of touch 95 
Increased perception of colour 85 
Full of energy 95 
Calm and relaxed 80 
Talkative 80 
Distorted Vision 65 
Hallucinations 60 
Confused thought 50 
Table 1.1: Self-reported psychological effects on-MDMA. Derived from Davison and Parrott (1997). 
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impaired heat dissipation (Rusyniak and Sprague, 2005, Simon, 1993). When a change in core 
body temperature occurs, many autonomic processes are initiated, mostly via signals from the 
hypothalamus. Autonomic responses to increased body temperature include sweating and 
cutaneous vasodilation (Rusyniak and Sprague, 2005, Sessler, 1997). In hyperthermic states, 
the temperature set-point of the hypothalamus is normal, however the peripheral mechanisms 
are unable to maintain body temperature that matches the set-point (Simon, 1993). This differs 
from fever as fever occurs when the hypothalamic set-point is increased due to the action of 
circulating pyrogenic cytokines, causing peripheral mechanisms to conserve and generate heat 
until body temperatures rise to the new set-point (Dinarello et al., 1988). An ecstasy overdose 
victim presents with symptoms like those described as “serotonin syndrome” due to an excess 
of serotonin (5-hydroxytryptamine; 5-HT) in the synapse, which is associated with drugs that 
affect the 5-HT system (Sun-Edelstein et al., 2008). Symptoms such as hyperactivity, confusion 
and jaw clenching are considered normal effects of ecstasy, however some users develop the 
more serious complication of hyperthermia. 
 1.3.3 Long-term adverse effects 
In addition to the acute adverse effects associated with MDMA, there are many long-term 
problems associated with its continued use. Users report feelings of lethargy, irritability, 
moodiness, insomnia, paranoia and depression in the days following MDMA use (Davison and 
Parrott, 1997, Green et al., 2003). It has been suggested that MDMA use could lead to the 
development of depression due to long-term depletion of 5-HT that has been observed in both 
humans and animals (Malberg and Seiden, 1998, McCann et al., 1998, Wang et al., 2004).  
Studies have shown that ecstasy users have reduced serotonin transporter (5HTT) levels, an 
indicator for loss of 5-HT neurons (McCann et al., 1998, Reneman et al., 2002a, Reneman et 
al., 2002b). There is also a history of long-term cognitive impairment problems associated with 
ecstasy use (Parrott and Lasky, 1998, Fox et al., 2001). In a study conducted in individuals with 
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low exposure to other recreational drugs, MDMA users displayed deficits in mental processing 
speed and impulsivity compared to non-users (Halpern et al., 2004). Another group found that 
MDMA users showed higher impulsivity and lower decision making performance compared 
to cannabis users and non-drug users (Quednow et al., 2007), as well as memory deficits 
compared to the same control groups (Quednow et al., 2006). 
1.4 Mechanisms of action of MDMA 
The mechanisms of action of MDMA are currently not fully understood, however it is well 
known to have a stimulant effect. MDMA acutely increases extracellular concentrations of 
neurotransmitters such as 5-HT, dopamine (DA), noradrenaline (NA), and acetylcholine (ACh) 
in the central nervous system (CNS), as well as having direct agonist action on pre- and 
postsynaptic receptors for these neurotransmitters (Cole and Sumnall, 2003). MDMA increases 
neurotransmitter concentration in the brain in several ways (Fig. 1.3). It acts as a competitive 
reuptake inhibitor at vesicular and plasma membrane reuptake transporters, and reverses their 
action so high amounts of neurotransmitter (5-HT, DA, NA) are left lingering in the synaptic 
cleft (Cole and Sumnall, 2003, Miller, 2011). After entering the neuron, MDMA also enhances 
the release of monoamines from storage vesicles via a carrier-mediated mechanism after 
entering vesicles through vesicular monoamine transporters (VMAT) (Partilla et al., 2006). 
MDMA also inhibits tryptophan hydroxylase (TPH) through sulphydryl oxidation to decrease 
the synthesis of 5-HT and contribute to long-term serotonin depletion (Nishisawa et al., 1999, 
Kuhn and Geddes, 2000, Schmid and Kehne, 1990). MDMA inhibits monoamine oxidase 
(MAO), which is involved in breaking down these monoamines resulting in increased 
monoamine binding at postsynaptic receptors (Leonardi and Azmitia, 1994). As previously 
mentioned, MDMA works to increase release of NA (Rothman et al., 2001), which potentiates 
NA-induced smooth muscle contraction (Al-Sahli et al., 2001), as well as dopamine which is 
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likely responsible for amphetamine-like psychostimulant effects of MDMA (Green et al., 2003, 
Beardsley et al., 1986). It elicits brain release of ACh (Acquas et al., 2001, Fischer et al., 2000) 
as well as acutely increases hormones such as cortisol (Connor et al., 1999), oxytocin, and 
vasopressin (Forsling et al., 2002), which may be involved in psychological and psychomotor 
stimulant effects of MDMA. MDMA also causes pronounced changes in immune function such 
as reducing numbers of circulating lymphocytes, reducing T-cell proliferation and 
immunoglobin production, and increases in cytokine production and release (Connor et al., 
1998, Connor et al., 2000, House et al., 1995). 
 
Figure 1.3: Diagrammatic representation of the main pharmacological effects of MDMA at the neuronal 
serotonergic terminal and synapse. 1) MDMA enters the neuron via monoamine transporters (5-HTT) acting as a 
substrate and produces competitive reuptake inhibition. 2) MDMA inhibits TPH, the rate limiting enzyme for 5-
HT synthesis resulting in long-term depletion of 5-HT. 3) MAO, the enzyme responsible for 5-HT degradation is 
partially inhibited by MDMA. 4) MDMA produces an acute and rapid release of 5-HT from storage vesicles 
entering through VMAT and releasing vesicular stores via a carrier-mediated exchange mechanism. 5) MDMA 
promotes rapid release of intracellular 5-HT via reversal of 5-HTT activity. 6) MDMA administration results in 
increased serotonin binding and 5-HT receptor activity. 7) MDMA agonist activity on post-synaptic receptors. 
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1.5 Pharmacokinetics of MDMA 
 1.5.1 Humans 
MDMA is usually taken orally and is sold in the form of tablets or capsules featuring various 
designs and colours. MDMA is produced in a racemic mixture where the S(+) isomer of 
MDMA (80-120 mg effective dose) is more potent causing euphoria and a number of other 
desirable effects compared to its R(-) isomer (300 mg effective dose), which predominantly 
causes its mescaline-like effects (Fantegrossi et al., 2003, De la Torre et al., 2004, Parrott, 
2004). However, the dose and purity of ‘ecstasy’ tablets containing MDMA may differ between 
batches, and some batches may not contain MDMA at all, but rather be a mix of similar 
substances such as MDA, MDEA, or PMA (Parrott, 2004, Capela et al., 2009). One tablet of 
MDMA contains on average 80-150 mg of MDMA (Green et al., 2003) however, this can range 
as high as 245 mg per tablet (Morefield et al., 2011). It is common for users to consume 1-2 
tablets over a short period of time (Parrott, 2001), however, there have been reports of users 
consuming in excess of 5 or 10 tablets (Morefield et al., 2011). 
Following oral consumption, MDMA is absorbed from the gastrointestinal tract into the 
bloodstream. The onset of MDMA’s effects usually takes between 20 to 60 min to occur, with 
peak effects occurring between 60 to 90 min after drug consumption. The acute effects of 
MDMA last for several hours following initial drug administration (Green et al., 2003). 
Following oral ingestion of MDMA by humans (50-125 mg), its maximum plasma 
concentration (Cmax) appears at approximately 2 hours with a half-life of 8 hours (De la Torre 
et al., 2004). Elimination of MDMA after a single dose occurs approximately 40 hours after 
administration and its elimination half-life is approximately 8-9 hours, significantly lower than 
other stimulant drugs such as methamphetamine (10-12 hours) and amphetamine (12-15 hours) 
at similar doses (De la Torre et al., 2004). Plasma and brain concentrations of MDMA are not 
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proportional to administration of an increased dose of drug. These non-linear pharmacokinetics 
can be explained by saturation of MDMA’s metabolism at high doses, as well as the interaction 
between metabolites of MDMA with enzymes involved in its own metabolic pathways (De la 
Torre et al., 2004, De la Torre et al., 2000). Therefore, saturation of MDMA metabolism can 
occur after the repeated administration of MDMA and can cause fatal MDMA intoxication. 
 1.5.2 Animals 
There is a wealth of pharmacodynamic data demonstrating the effects of MDMA in animals, 
however, there are fewer studies concerning MDMA pharmacokinetics (Chu et al., 1996, 
Baumann et al., 2009, Concheiro et al., 2014), and even fewer related to the relationship 
between pharmacodynamics and pharmacokinetics (Chu et al., 1996). Studies on MDMA 
pharmacokinetics undertaken in animals are crucial to help improve our understanding and 
interpretation of animal based MDMA studies, and how they relate to the drugs’ effects in 
humans. A study by Baumann et al., (2009) investigated how different dose and route of 
administration affected MDMA pharmacokinetics in rats. They demonstrated that a low oral 
dose of MDMA (2 mg/kg) produced low MDMA concentrations, whereas high dose (10 
mg/kg) intraperitoneal (i.p.) administration produced high concentrations of MDMA 
(Baumann et al., 2009). The half-life of the drug was 45 min in rats given 2 mg/kg orally, 
significantly shorter than the half-life in humans of about 7-9 hours (De la Torre et al., 2000). 
The higher dose of MDMA (10 mg/kg) had a half-life of 1 hour, suggesting that a longer time 
for drug elimination occurs at higher doses and when administered intraperitoneally. This study 
also found that low dose MDMA (2 mg/kg) produced plasma Cmax values of ~200 ng/ml. 
Similar studies demonstrated that MDMA doses of 2.5 mg/kg administered subcutaneously 
(s.c.), and 3 mg/kg administered i.p. resulted in Cmax of 164 ng/ml and 300 ng/ml respectively, 
results comparable to humans given recreational doses (1.3 – 1.7 mg/kg) under controlled 
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conditions (De la Torre et al., 2000). Similar to Baumann et al., (2009), a 1 hour half-life of 
MDMA was found at low dose (2.5 mg/kg, s.c.), still significantly reduced compared to human 
drug consumption (De la Torre et al., 2000). Like humans, rats have non-linear MDMA 
pharmacokinetics with MDMA concentrations in the rat brain increasing non-linearly with 
dose (Chu et al., 1996). High dose MDMA (10 mg/kg, s.c.) was found to increase plasma 
MDMA concentrations in Sprague-Dawley rats 10-fold compared to low dose MDMA (2.5 
mg/kg, s.c.), while in the same animals the MDMA metabolites (±)-3,4-
dihydroxymethamphetamine (HHMA) and (±)-4-hydroxy-3-methoxymethamphetamine 
(HMMA) saw only a 2-fold increase (Concheiro et al., 2014). This is thought to be due to 
metabolic inhibition of MDMA at high doses (Concheiro et al., 2014). 
 1.5.3 Metabolism 
The pharmacological effects of MDMA in humans and animals can be complicated by the 
extensive hepatic metabolism it undergoes after the drug is absorbed and distributed throughout 
the body. There are two main pathways (Fig. 1.4) that are involved in the metabolism of 
MDMA once it reaches the liver (Maurer et al., 2000, De la Torre et al., 2004). In the first 
pathway, MDMA undergoes O-demethylation by cytochrome P450 (CYP) CYP2D6, 1A2, 2B6 
and 3A4 in humans, and by CYP2D1 and 3A2 in rats, to form HHMA, which undergoes O-
methylation to form HMMA by catechol-O-methyltransferase (COMT) (Concheiro et al., 
2014). Within the second pathway, MDMA undergoes N-demethylation by CYP2B6, 1A2, and 
2D6 in humans, and CYP1A2 and 2D1 in rats, to form MDA, which is then O-demethylated 
in a similar fashion to MDMA to form  3,4-dihydroxyamphetamine  (HHA), which is then 
subsequently metabolised by COMT to form 3-methoxy,4-hydroxyamphetamine (HMA) 
(Concheiro et al., 2014). The HHMA and HHA metabolites of MDMA and MDA undergo 
conjugation with glutathione and the resulting conjugates are thought to contribute to the long-
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term neurotoxic effects of MDMA (Green et al., 2003, de la Torre and Farré, 2004, Capela et 
al., 2009). Metabolites such as HHA, and HMA have been shown to induce 5-HT toxicity in 
rats when administered subcutaneously, and the metabolites 5-(GSH)-α-MeDA, 5-(NAC)-α-
MeDA, 5-(NAC)-N-Me-α-MeDA, and 2,5-(GSH)-α-MeDA were demonstrated to cause 
long-term 5-HT neurotoxicity in rats when undergoing direct intra-striatal administration 
(Capela et al., 2009). The elimination of MDMA occurs when the hydroxylated metabolites of 
MDMA are excreted in the urine as glucuronide and sulphate conjugates. The main differences 
between human and rat metabolism of MDMA involves the specific CYP isoforms involved in 
each species’ metabolism, the shorter MDMA and metabolite half-life in rats, as well as the 
propensity for rats to form more MDA than in humans, and the formation of glucuronide-
conjugated metabolites predominating in rats (Maurer et al., 2000, De la Torre et al., 2004). 
Metabolic differences between species are a major limitation when attempting to extrapolate 
data from animal models to humans. Extrapolation of results from animal models to humans 
implies that the metabolic disposition of MDMA among the species is similar and that the 
metabolic disposition is comparable (de la Torre and Farré, 2004). However, there are 
numerous differences in MDMA metabolism between rats and humans. N-demethylation of 
MDMA to MDA is the main metabolic pathway in rats compared to O-demethylenation of 
MDMA to HHMA in humans (De la Torre et al., 2004) resulting in differing production rates 
of HHMA and HMMA between rats and humans. This is relevant as thioether adducts with 
quinones formed from autooxidation of the MDMA metabolites HHMA and HHA are the most 
likely chemical species involved in 5-HT neurotoxicity as previously stated (de la Torre and 
Farré, 2004, Capela et al., 2009). Furthermore, differences in enzyme kinetics and enzyme 
inhibition between rats and humans suggests that each species experiences different rates of 
formation for neurotoxic metabolites (Bowyer et al., 2003, Bogaards et al., 2000). The 
inconsistencies between species regarding metabolic disposition, and non-linear kinetics within 
Chapter 1 – Research Background 
 
Stefan Musolino, PhD Thesis 2019  14 
the main metabolic pathways limits allometric scaling across animal models, and complicates 
the extrapolation of results to human studies. 
 
Figure 1.4: Pathways involved in the metabolism of MDMA in rats and humans. The CYP450 enzymes involved 
in rats are coloured blue, the enzymes involved in humans are coloured red.  Derived from de la Torre and Farre 
(2004). 
1.6 Effects of MDMA in animals 
 1.6.1 Disruption of thermoregulation 
Previous animal studies have used systemic doses of 10-15 mg/kg MDMA to produce 
consistent changes (including both increases and decreases) in body temperature, 
neurotransmitter release, behaviour, and a wide range of other physiological parameters 
without causing fatalities (Daws et al., 2000, Freezer et al., 2005, Stanley et al., 2007, Anderson 
et al., 2011). The drug doses used in these studies results in similar MDMA plasma 
concentrations observed in humans, thus making the results in animals comparable to 
recreational human usage (Colado et al., 1995, Chu et al., 1996, Green et al., 2003). 
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Hyperthermia is the major acute effect of MDMA administration and can last several hours 
following drug use. Previous findings have demonstrated hyperthermia (+1-2 °C) in response 
to MDMA with temperatures peaking between 40-60 min after systemic MDMA 
administration (Malberg et al., 1996, Mechan et al., 2002, Orio et al., 2010, Anderson et al., 
2011). Like human MDMA use, animals studies have shown that the degree of MDMA-
induced hyperthermia is affected by environmental factors such as ambient temperature, social 
interaction, and diminished heat dissipation (Dafters and Lynch, 1998, Malberg and Seiden, 
1998, Brown and Kiyatkin, 2004). Dafters and Lynch (1998) demonstrated that MDMA (10-
15 mg/kg) resulted in significant body temperature increases (+2.3 °C) at normal ambient 
temperature (22 °C), however, significant body temperature decreases (-2.7 °C) were observed 
at an ambient temperature of 17 °C. Malberg and Seiden (1998) showed that higher doses of 
MDMA (20-40 mg/kg) resulted in hyperthermia at ambient temperatures between 28-30 °C, 
whereas hypothermia was observed between 20-22 °C. Brown and Kiyatkin (2004) found that 
when administered under quiet resting conditions, MDMA (9 mg/kg) caused no significant 
increases in brain or body temperature, however, significant temperature increases in both the 
brain and body were seen during male-female social interaction, during jugular vein occlusion, 
and when administered at a high ambient temperature of 29 °C. This study also found that brain 
areas showed consistently faster temperature increases and to greater elevations (+0.4 - 0.8 °C) 
when compared to the body under warm environmental conditions (Brown and Kiyatkin, 
2004). This suggests that physiological mechanisms of drug-induced metabolic neural 
activation (Gordon et al., 1991, Quate et al., 2004, Darvesh et al., 2002) and diminished heat 
dissipation (Brown and Kiyatkin, 2004, Kiyatkin et al., 2014, Nybo et al., 2002) result in 
increased intra-brain heat production, which can be viewed as the primary cause of brain 
hyperthermia, and a contributor to a delayed and weaker body hyperthermia (Brown and 
Kiyatkin, 2004). 
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Neurotransmitters that contribute most to MDMA-induced hyperthermia have long been the 
subject of debate. It is well-known that MDMA-induced hyperthermia involves release of 5-
HT (Freezer et al., 2005, Stanley et al., 2007), however DA release has also been implicated in 
the hyperthermic response (Mechan et al., 2002, Blessing et al., 2003). Several studies have 
used 5-HT and DA uptake inhibitors and receptor antagonists to investigate these 
neurotransmitters’ contribution to the hyperthermic response, however, these studies produced 
variable results. Mechan et al. (2002) demonstrated that a dose of 12.5 mg/kg at normal ambient 
temperature produced a significant increase in rectal temperature. They also demonstrated that 
pretreatment of animals with several 5-HT receptor antagonists and uptake inhibitors prior to 
MDMA administration failed to significantly attenuate this hyperthermic response. In contrast, 
pretreatment with the DA D1 receptor antagonist SCH 23390 (0.3-2 mg/kg) was effective in 
preventing these observed increases in body temperature. Other microdialysis studies have also 
shown that increases in extracellular 5-HT have no association with increases in body 
temperature (Freezer et al., 2005, Stanley et al., 2007). They have also shown that 
administration of 5-HT uptake inhibitors, such as fluoxetine, block increases in extracellular 5-
HT but have no effect on hyperthermia (Schmidt et al., 1990, Berger et al., 1992, Malberg et 
al., 1996). In contrast, Malberg et al. (1996) reported that pretreatment with 6 mg/kg of the 5-
HT2A receptor antagonist ketanserin, and 75 mg/kg of the tyrosine hydroxylase inhibitor α-
methyl-p-tyrosine (AMPT) was successful in preventing the hyperthermic effects of a much 
higher 40 mg/kg dose of MDMA at normal ambient temperature. Blessing and Seaman (2003) 
showed that activation of post-synaptic 5-HT2A receptors caused cutaneous vasoconstriction 
and hyperthermia in both rats and rabbits (Blessing and Seaman, 2003), whereas activation of 
inhibitory presynaptic 5-HT1A receptors lead to vasodilation and decreases in body temperature 
(Ootsuka and Blessing, 2003). This group also demonstrated that MDMA’s temperature effects 
work via a vasoactive mechanism (Blessing et al., 2003). They found that administration of 10 
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mg/kg MDMA induced increases in body temperature of between 1.5-2 °C, which was 
accompanied by a 50% decrease in tail artery blood flow, indicating vasoconstriction. 
Administration of clozapine, an antipsychotic agent with antagonistic action at DA D4 receptors 
and action at several 5-HT and muscarinic receptors, reversed both the temperature and 
vasoconstrictive effects of MDMA, and promoted increased blood flow. More recent work has 
identified peripheral vasoconstriction as a critical mechanism underlying the activity and state-
dependent potentiation of MDMA-induced brain hyperthermia under different environmental 
conditions (Kiyatkin et al., 2014). These results, although variable, suggest that both 5-HT and 
DA play a role in the thermoregulatory effects of MDMA. 
In addition to neurotransmitters, microglial activation and pro-inflammatory cytokines such as 
interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) are known to 
increase body temperature by acting directly or indirectly in the brain. IL-1β, in particular, is 
known to be involved in the development of hyperthermia in response to exogenous pyrogens 
such as lipopolysaccharide (Klir et al., 1994), turpentine (Luheshi et al., 1997), and leptin 
(Luheshi et al., 1999). Furthermore, administration of the interleukin-1 receptor antagonist (IL-
1RA) inhibits the rise in temperature caused by these inflammatory stimuli in experimental 
animals. It has been demonstrated that immediately after administration of MDMA, an acute 
increase in IL-1β concentration is observed in the hypothalamus and frontal cortex, peaking at 
3 h post-MDMA administration (Orio et al., 2004, O’Shea et al., 2005). However, Orio et al. 
(2004) demonstrated that IL-1β release is likely a consequence of MDMA-induced 
hyperthermia rather than its cause.  Their results displayed a clear dissociation between 
hyperthermia and IL-1β release with marked hyperthermia visible within the first 20 min of 
MDMA administration (Colado et al., 1993), peaking at 60 min, compared to IL-1β release, 
which peaked 3 h post-MDMA. Furthermore, interleukin-1 receptor antibodies did not modify 
peak hyperthermia following MDMA administration, and abolishment of hyperthermia by 
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maintaining animals at low ambient temperature (4 °C) resulted in reduced IL-1β release (Orio 
et al., 2004). Inhibition of microglial activation and IL-1β release by the cannabinoid CB2 
receptor agonist JWH-015 has also been shown to have no effect on the acute hyperthermic 
response (Torres et al., 2010). Contrary to these findings however, O’Shea et al. (2005) showed 
that pretreatment with an intracerebroventricular injection of IL-1β 30 min prior to MDMA 
(12.5 mg/kg) increased the temperature response to MDMA. Administration of IL-1β in control 
animals treated with saline also produced an increase in rectal temperature compared with 
vehicle-treated controls (O’Shea et al., 2005). Thermoregulation is known to be affected by 
changes in both neural, and neuroinflammatory pathways. Therefore, it is likely that MDMA-
induced variations in both neurotransmitter and pro-inflammatory cytokine concentrations 
contribute to its disruptive thermoregulatory effects. 
1.6.2 Behavioural effects 
In addition to hyperthermia, activation of serotonergic, dopaminergic, and noradrenergic 
pathways by MDMA differentially associated with specific behaviours. MDMA produces 
acute ‘serotonin syndrome’ in animals, which is most likely attributed to increases in 
extracellular 5-HT levels in multiple brain regions. Serotonin syndrome is characterised by 
hyperactivity, head-weaving, fore-paw treading, piloerection, proptosis, penile erection, 
ejaculation, salivation, and defecation (Spanos and Yamamoto, 1989). Administration of MAO 
inhibitors, L-tryptophan (Grahame‐Smith, 1971b), non-selective 5-HT agonists (Grahame‐
Smith, 1971a), and 5-HT1A agonists (Goodwin and Green, 1985) have been shown to produce 
this syndrome, thus highlighting the importance of increased 5-HT activity on MDMA-induced 
behavioural changes. 
In contrast, activation of the dopaminergic system has been linked to increases in locomotor 
activity (LMA) and stereotypical gnawing (Robinson and Becker, 1986, Bankson and 
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Cunningham, 2001, Yamamoto and Spanos, 1988). MDMA administration causes dose-
dependent increases in spontaneous LMA and this behavioural change occurs immediately 
after drug administration (Dafters, 1994). MDMA has been shown to produce a release of 
dopamine both in vitro (Stone et al., 1986) and in vivo (Yamamoto and Spanos, 1988) and its 
release has been paralleled with the time-course of hyperlocomotion in rats (Spanos and 
Yamamoto, 1989). However, lesions of the mesolimbic DA system have been shown to be 
associated with only partial attenuation of MDMA-induced hyperlocomotion (Gold et al., 
1989), and 5-HT release alone is insufficient to increase LMA (Aulakh et al., 1988). Therefore 
an interaction between DA and 5-HT may underlie MDMA-induced hyperlocomotion  
(Bankson and Cunningham, 2001). Kehne et al (1996) showed that the dose-dependent increase 
in LMA was attenuated by pretreatment with the 5-HT2A receptor antagonist MDL 100907 
(Kehne et al., 1996). Callaway et al (1990) found similar reductions in MDMA-induced 
hyperlocomotion using the 5-HT uptake inhibitor fluoxetine (Callaway et al., 1990). This 
suggests that 5-HT mediated DA release, as well as direct 5-HT receptor agonist activity are 
involved in MDMA-induced increases in LMA.  
Increases in extracellular NA have also been linked to the behavioural effects associated with 
MDMA use. These effects include emotional excitation, anxiety, as well as blissful state, and 
the experience of unity (Hysek et al., 2011). The magnitude of subjective effects caused by 
MDMA in humans correlates with its potency to release NA (Rothman et al., 2001). This is 
supported by results showing that inhibition of the noradrenaline transporter (NAT) reversed 
the acute cognitive effects of MDMA in rhesus monkeys (Verrico et al., 2008). Similar results 
were replicated in humans with NAT inhibitors attenuating the subjective response to both 
MDMA (Hysek et al., 2011), and D-amphetamine (Sofuoglu et al., 2009). 
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1.6.3 Cardiovascular effects 
Administration of MDMA in rats produces cardiovascular changes, in addition to variations in 
brain and body temperatures and LMA that are consistent with its effects on monoamine 
pathways in the brain (Green et al., 2003, Bexis and Docherty, 2006, Jaehne et al., 2008). The 
cardiovascular response to ambient temperature is closely related to core temperature and is a 
mechanism for heat production in rats (Chambers et al., 2000). Therefore, increases in HR, and 
other cardiovascular parameters such as blood pressure, may provide indication for increases 
in heat production and impairment of thermoregulation in animals (Gordon et al., 1991, Jaehne 
et al., 2011). Acute MDMA administration produces cardiac stimulation, tachycardia, and 
arrhythmia (Gordon et al., 1991) whilst also facilitating vasoconstriction in rats and rabbits 
(Fitzgerald and Reid, 1994, Pedersen and Blessing, 2001). These cardiovascular effects may 
potentially be caused by the actions of MDMA displacing NA from adrenergic nerve terminals 
(Fitzgerald and Reid, 1993) and its subsequent effect on adrenoreceptors. MDMA users have 
been reported to display increased plasma catecholamine levels, potentially due to 
noradrenergic hyperactivity (Stuerenburg et al., 2002). MDMA has also been shown to have 
direct agonist action on peripheral (Lavelle et al., 1999) and central α1 and α2 adrenoreceptors 
both in vitro and in vivo (McDaid and Docherty, 2001) and may also competitively block the 
NA transporter to increase extracellular NA concentrations (Al-Sahli et al., 2001). Studies 
show that agonist action at α1 and α2 adrenoreceptors contribute to MDMA’s blood pressure 
effects in rats (McDaid and Docherty, 2001, Rajamani et al., 2001) with the α2A receptor 
involved with its hyperthermic response in mice (Bexis and Docherty, 2005). These 
cardiovascular changes are compounded by increased renin and angiotensin II (AII) production 
induced by MDMA (Burns et al., 1996). In addition to its own vasoconstrictive effects, AII 
promotes aldosterone release from the adrenal cortex leading to increases in blood pressure. 
Furthermore, MDMA causes hyponatremia by increasing secretion of anti-diuretic hormone 
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(ADH) which also has moderate vasoconstrictive effects (Bora et al., 2016, Irvine et al., 2006). 
It is compounded by the excessive intake of hypotonic liquid accompanied by hyperthermia in 
MDMA users (Bora et al., 2016). Hyponatremia, in addition to previously described vascular 
changes, are a primary contributor to the potentially deadly adverse effects associated with 
human MDMA use such as intracerebral haemorrhage and brain oedema (Fitzgerald and Reid, 
1994, Wolff et al., 2006). Interestingly, MDMA reportedly does not alter 5-HT induced aortic 
contraction (Cannon et al., 2001, Murphy et al., 2002). However, the selective serotonin 
releasing agents (SSRA) 4-methylthioamphetamine and 4-methylthiomethamphetamine are 
potent inhibitors of 5-HT mediated vascular contraction (Murphy et al., 2002). Neurotoxic 
MDMA regimens have also been shown to alter cardiovascular function through actions on 
both descending peripheral and central 5-HT pathways (O'Cain et al., 2000) indicating that 
cardiovascular changes induced by MDMA are partially 5-HT-mediated. 
1.6.4 Long-term effects 
Like human MDMA use, chronic MDMA administration in animals has been linked to the 
long-term depletion of 5-HT, and other serotonergic components in the brain. It has been shown 
to lead to serotonergic problems in the brain such as a decrease in tryptophan hydroxylase 
(Stone et al., 1988), 5-HT and 5-HIAA (Schmidt et al., 1986, Clemens et al., 2004, Callaghan 
et al., 2006, Wang et al., 2004), a loss of 5-HT uptake sites (Battaglia et al., 1988), 5-HT 
terminal degeneration (O'Hearn et al., 1988), reduction of 5-HTT binding (Green et al., 2003), 
and impairment of 5-HT function (Hatzidimitriou et al., 1999). Callaghan et al (2006) 
demonstrated that MDMA (10-20 mg/kg) caused significant reductions in cortical 5-HTT 
binding, 5-HT content, and 5-HIAA concentrations in rats two weeks after repeated drug 
administration. Wang et al (2004) showed similar results after two weeks of repeated 
administration with MDMA (7.5 mg/kg) resulting in a 50% reduction in 5-HT concentration 
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across multiple brain areas. Clemens et al (2004) used albino Wistar rats to demonstrate that 
MDMA (5 mg/kg) had similar neurotoxic effects on 5-HT systems for as long as seven weeks 
after an initial two days of repeated drug administration. 
The long-term neurotoxic effects of MDMA can be exacerbated when administered at high 
ambient temperature resulting in hyperthermia. Broening et al (1995) administered MDMA (20 
or 40 mg/kg) to rats aged 40-70 days at varying ambient temperatures. Rats displayed a 
significant hyperthermia at ambient temperatures of 25 and 30 °C, and showed larger decreases 
in cortical 5-HT one week after drug administration. Malberg and Seiden (1998) displayed 
similar findings when MDMA (20 and 40 mg/kg) was administered at different ambient 
temperatures. Rats administered MDMA at ambient temperatures between 26-30 °C showed 
greater increases in body temperature as well as significant decreases in cortical 5-HT 
concentrations two weeks after drug administration compared to rats administered MDMA at 
20-22 °C. It has been suggested that hyperthermia’s influence on serotonergic neurotoxicity 
has been linked to dopamine receptor activity (Malberg et al., 1996, Malberg and Seiden, 1998, 
Yuan et al., 2002, Yuan et al., 2001). However, MDMA has been shown to induce increased 
concentrations of both 5-HT and DA in the nucleus accumbens at an ambient temperature of 
30 °C compared to 20 °C (O'Shea et al., 2005), therefore 5-HT receptor activity is likely also 
implicated in this increased severity. Low ambient temperature has been shown to have a 
protective effect on MDMA-induced reductions in brain 5-HT levels. MDMA administration 
at ambient temperatures of 10 °C and 22 °C resulted in decreases in core body temperature and 
either no, or smaller decreases in brain 5-HT concentrations compared to those treated at higher 
ambient temperatures (Broening et al., 1995, Malberg et al., 1996). In contrast to this, other 
studies have found that pretreatment with drugs such as fluoxetine and mazindol protected 
against 5-HT neurotoxicity without attenuating MDMA-induced hyperthermia (Shankaran and 
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Gudelsky, 1999, Falk et al., 2002), suggesting that a mechanism unrelated to hyperthermia is 
responsible for the increased severity of 5-HT neurotoxicity. 
1.7  Conventional methodological approaches to assess MDMA temperature effects 
in  animals 
Previous studies have utilised many different methods to determine the thermoregulatory, 
neurochemical and physiological effects of MDMA within animal models. However, the 
different methods used to monitor these effects have produced many confounding results that 
make data comparison between these studies difficult and translational relevance to human 
MDMA use hard to assess. These contradictory results are summarised in Table 1.2. The results 
of this table clearly outline the importance of the selected materials and methodology, 
especially when examining the thermoregulatory effects of MDMA.  
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 1.7.1 Rectal probes 
Rectal temperature measurement has been used in the past to assess the effects of MDMA on 
core body temperature (Stanley et al., 2007, Colado et al., 1995, Zhang et al., 2006, Anderson 
et al., 2011, Orio et al., 2010, Gordon et al., 1991). Rectal temperature is usually measured 
from thermistor probes inserted 5-9 cm into the rectum (Poole and Stephenson, 1977). For 
continuous temperature measurement rats are often placed in a restraining device (Feldberg 
and Saxena, 1975) or an enclosure small enough to restrict their movement (Stoner, 1971), 
however for intermittent measurements, animals are allowed to move freely around their 
enclosure except when restrained to permit insertion of the probe. Although this method seems 
advantageous requiring no surgery prior to experiments to permit temperature measurements, 
the need for restraint offers a profound disadvantage as it has been shown to interfere with 
normal thermoregulation (Martin and Papp, 1979, Frankel, 1959). The requirement for constant 
handling and repeated insertion of the rectal probe into the rectum can also produce stress-
induced increases in body temperature (Gordon, 1990), brain temperature (Bae et al., 2007), as 
well as effects on HR, blood pressure, and LMA (Guiol et al., 1992, Van Den Buuse, 1994, 
Irvine et al., 1997). This may contribute to conflicting reports of the effect of MDMA on core 
body temperature in studies using rectal thermometers. For example, when core body 
temperature was measured with a rectal probe at normal ambient temperature, core temperature 
increased in response to MDMA (Anderson et al., 2011, Orio et al., 2010, Colado et al., 1995). 
Contrary to this, when measured with non-restrictive methods such as radio telemetry, core 
body temperature decreased at normal ambient temperature (22 oC) (Bexis and Docherty, 
2006), a result consistent with previous studies reporting hypothermia at low or normal ambient 
room temperature (Malberg and Seiden, 1998). Elimination of restraint and stress-inducing 
probe insertion from the recording procedure reduces the confounding effects on body 
temperature (Clement et al., 1989, Dilsaver et al., 1990) as well as HR, blood pressure, and 
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LMA (Irvine et al., 1997, Guiol et al., 1992, Van Den Buuse, 1994, Gegout-Pottie et al., 1999). 
Previous studies have shown core body temperature measurement in rats using rectal probes 
and thermosensor telemetry produce qualitatively similar, but quantitatively different results 
(Dilsaver et al., 1990). This has led to more recent research utilising telemetric sensors for the 
continuous monitoring of core body temperature, as well as other physiological parameters in 
free-moving animals (Bexis and Docherty, 2005, Jaehne et al., 2005, Bexis and Docherty, 
2006). 
 1.7.2 Radiotelemetry 
Telemetry was first used in an ecology study in 1959 (LeMunyan et al., 1959), however since 
this time, telemetry transmitters have been enhanced to be smaller, and more durable with 
longer life expectancies. These transmitters were initially used only to monitor core body 
temperature, however, since then, this technique has evolved to measure numerous 
physiological and behavioural parameters including cardiovascular (Rubenson et al., 1984), 
LMA (Clement et al., 1989), and HR variables (Gordon et al., 1991). They can be used to 
gather physiological data in awake, freely-moving animals without the need for restraint or 
restrictive caging to perform temperature measurements. Instead, an implantable transmitter is 
used to transmit data to a receiver consolidation matrix linked to a computer equipped with 
data acquisition software (Fig. 1.5) (Guiol et al., 1992, Rodsiri et al., 2011). These transmitters 
are surgically implanted prior to experimentation and when activated can continuously transmit 
data via radio signals to the nearby receiver, which is then collected by a data acquisition 
program running on a nearby computer. As mentioned previously, this technique has been used 
in the past to assess the effects of MDMA in animal models (Bexis and Docherty, 2005, Jaehne 
et al., 2005, Daws et al., 2000, Bexis and Docherty, 2006). Bexis et al. (2006) found that a 
high dose of MDMA (20 mg/kg, s.c.) at normal ambient temperature resulted in a prolonged 
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hypothermic response (Bexis and Docherty, 2006). At high ambient temperature (30 oC), 
Daws et al. (2000) found that a modest dose of MDMA (10mg/kg, i.p.) caused a slight 
increase in core body temperature and LMA (Daws et al., 2000). Jaehne et al. (2005) found 
that the same dose of MDMA caused a more prolonged and intense increase in core body 
temperature and LMA, as well as an increase in HR when administered at high ambient 
temperature (Jaehne et al., 2005), however, methodological differences regarding animal 
confinement during core temperature measurements could explain the differences between 
these studies. Although the effects of MDMA on core body temperature have been studied 
extensively in the past, the temperature effects of MDMA in the brain have only been 
investigated within the last two decades (Kiyatkin et al., 2002, Brown and Kiyatkin, 2004). 
 
Figure 1.5: Diagram of radiotelemetry technique setup. 
1.7.3 Thermocouples 
The majority of studies concerned with MDMA-induced hyperthermia have historically 
focused exclusively on MDMA’s effect on body temperature (Gordon et al., 1991, Colado 
et al., 1995, Malberg et al., 1996, Malberg and Seiden, 1998, Daws et al., 2000, Bexis et al., 
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2004, Orio et al., 2010). However, more recent studies show that brain tissue increases at a 
faster rate and to greater magnitude than muscle tissue in response to MDMA, and that brain 
hyperthermia may contribute to a delayed and weaker hyperthermia in the body (Brown and 
Kiyatkin, 2004). These changes in brain and muscle temperature were demonstrated using 
thermocouples to perform in vivo brain temperature monitoring (Kiyatkin, 2013). 
Thermocouples are conventional temperature probes that consist of two dissimilar metallic 
wires connected at one end creating a junction where temperature is measured. A unique 
voltage is produced at a given temperature and this voltage can then be measured and 
interpreted by a thermocouple thermometer. Thermocouples are usually inexpensive with 
good accuracy (~1 °C) and have relatively short response times. However, this strongly 
depends on probe diameter, and can be much shorter than 1 second (Schena et al., 2016). In 
addition to brain temperature monitoring, thermocouples have been previously utilised to 
perform temperature measurements during a variety of thermal ablation procedures for tumour 
treatment (Saccomandi et al., 2013). However, during these procedures, substantial 
thermocouple measurement error occur for two main reasons: 1) direct absorption of light 
by the metallic wires during laser ablation, and sonication during high-intensity focused 
ultrasound can result in substantial temperature overestimation (Banerjee and Dasgupta, 
2010, Manns et al., 1998); and 2) the high heat conductivity of the metallic wires can cause 
temperature overestimation at low temperatures, or underestimation at high temperatures 
(Rivens et al., 2007). The metallic wires can also potentially cause significant image 
artefacts in computed tomography (CT) or magnetic resonance (MR) guided thermal 
procedures (Schena et al., 2016). These thermal ablation procedures occur at extreme 
temperatures selected to cause death in tumorous cells, therefore these temperature artefacts 
would be unlikely to occur over the biologically relevant range between 35-45 °C. For 
example, Brown and Kiyatkin (2004) utilised copper-constantan thermocouples to show that 
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MDMA administration induced hyperthermia in both the brain and body that was 
exacerbated by numerous environmental conditions (Brown and Kiyatkin, 2004). Although 
thermocouples can be used to provide a means of localised temperature measurement within 
the brain, the method is not without its limitations. Optical fibre sensors are an attractive and 
advantageous alternative to traditional temperature measurement techniques devoid of many 
of the limitations present in traditional electrical sensors. 
1.8  Optical Fibres 
 1.8.1 Background 
Transmission of light through optical fibres plays a large role in our everyday lives. Optical 
fibres permit transmission of light over long distances and have many applications in 
telecommunications, computer networking, and power transmission in situations where 
metallic conductors present in conventional electrical systems are undesirable. Optical fibres 
operate based on the principle of total internal reflection. The core of an optical fibre has a 
higher refractive index than the surrounding fibre cladding, therefore light entering the fibre is 
reflected back into the core to propagate along its length as opposed to ‘leaking’ out into the 
periphery (Addanki et al., 2018). Approximately 40 years have passed since the manufacture 
of the first optical fibres (Powell, 1974, Sheem and Giallorenzi, 1979, Hocker, 1979) and they 
have since been developed for a wide range of applications (Fig 1.6) due to their inherent 
advantages such as low cost, small size, and increased durability. One of these applications is 
optical fibre sensors. Optical fibre sensors have many advantages when compared to 
conventional measurement techniques. These include immunity to electromagnetic 
interference (EMI), lightweight, small size, high sensitivity, large bandwidth, ease in signal 
light transmission, as well as the ability to provide multiplexed or distributed sensing (Lee, 
2003, Wade et al., 2003, Grattan and Meggitt, 1995). Optical fibres have found use in the 
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security and chemical industry, as well as in aircraft manufacture for temperature, pressure, 
fluid, and acceleration monitoring (Taylor and Cardimona, 2008, Addanki et al., 2018). They 
have also seen use for numerous biological sensing applications (Samset et al., 2001, Yoo et 
al., 2010, Webb et al., 2000, Tosi et al., 2016, Fajkus et al., 2017). However, despite their 
numerous advantages, only a limited number of optical fibre sensing techniques that have been 
successfully commercialised (Lee, 2003, Grattan and Meggitt, 1995, Culshaw and Dakin, 
1989). In many fields of application, optical fibres compete with mature, conventional 
techniques that are already well established within their field, and their installation cannot 
occur without the development of new infrastructure. To appeal to users already accustomed 
and comfortable with these technologies, the superiority of optical fibres needs to be made 
clear. Ideally, high performance sensor systems should be available at a reasonable price in the 
form of complete systems including detection and signal-processing electronics to increase 
their appeal and ease of use (Lee, 2003). 
    
Figure 1.6: Distribution of OFS-15 papers according to measurands. Derived from Lee (2003). 
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1.8.2 Optical fibre temperature sensors 
Temperature sensors make up a large portion of commercially available optical sensors and 
present an attractive alternative to conventional temperature measurement techniques for 
operation in thermally, chemically, and electromagnetically hazardous environments (Dos 
Santos et al., 1998). Fibre optic temperature sensors have previously found use in several 
different industries such as telecommunications and aerospace (Selker et al., 2006, Taylor and 
Cardimona, 2008, Bhatia, 1999), however, since the late 1990’s, they have also reached 
maturity as a sensing technology for biomedical applications (Tosi et al., 2018). Ongoing 
research in the field of optical fibre-based temperature sensors has focused on improving 
accuracy and measurement range, as well as reducing cost. There are many different techniques 
used to perform temperature sensing utilizing optical fibres, with the most common being fibre 
Bragg gratings (FBG) (Rai, 2007), however techniques such as long-period gratings and 
whispering gallery modes (WGM) have also been used (Guan et al, 2006, Lee and Nishii, 
1998).  These techniques have found use within structural health monitoring applications, 
however for temperature measurements requiring high resolution with high spatial precision, 
these methods are not ideal. Some examples of the temperature range, sensitivity, response 
time, and resolution of these techniques is given in Table 1.3. FBG show a relatively low 
response to temperature, which limits their resolution (Rao, 1997). Long-period gratings 
require long fibre lengths to obtain good sensitivity, limiting spatial resolution (Lee and Nishii, 
1998). WGM techniques are typically sensitive to changes in local refractive index making 
separation of the temperature from environmental changes challenging (Guan et al., 2006). 
Other methods for grating fabrication that can provide good sensitivity with good spatial 
precision (Guan et al., 2006) require complex fabrication techniques making them difficult to 
expand to commercial applications due to their high cost.  
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OFS Sensitivity Resolution Range Response time 
Fluorescence 0.5 μs °C-1 ± 0.5 °C 20-80 °C      a 
FBG 27 pm oC-1 0.1 °C 20-80 °C 100 ms 
FPI 0.19 nm oC-1 0.34 °C 25-80 °C 67 °C/sb 
Rayleigh scattering 10 pm oC-1 0.1 °C 20-46 °C 1 s 
LPG 62.9 nm oC-1 0.005 °C 20-100 °C 100 ms 
a No information available. b This is the rate of temperature change that 
 
the sensor can measure, rather than the response time. 
  
Table 1.3: Summary of key parameters of numerous types of optical fibre temperature sensors. Derived from 
Correia et al. (2018). 
1.8.3 Fluorescence Temperature Measurement 
One promising alternative method for temperature measurement utilising optical fibres 
involves rare-earth absorption and fluorescence monitoring. Rare-earth ions have been of 
interest for use in optical fibre temperature sensors because their absorption and emission 
properties depend on temperature (Berthou and Jörgensen, 1990, Dos Santos et al., 1998, 
Maciel et al., 1995). Rare-earth metals suitable for these temperature sensing applications have 
been studied extensively (Berthou and Jörgensen, 1990, Dos Santos et al., 1998, Maciel et al., 
1995, Wade et al., 1999, Rai et al., 2006, Rai and Rai, 2007). Materials deemed suitable for 
temperature sensing all contain pairs of energy levels where  small separations in the order of 
the thermal energy is seen. The principle of these sensors is based on the temperature-
dependent nature of light emitted from rare-earth ions. As temperature changes, populations in 
the energy level pairs change as the ions undergo thermal excitation to a higher energy state. 
By monitoring the upconversion emission from these ions, the temperature of the host medium 
can be discerned (Wade et al., 2003). Temperature sensors based on fluorescence have been 
used for many years and historically they made use of the temperature dependence of 
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fluorescence decay time (Grattan et al., 1987, Augousti et al., 1988). However, sensors based 
on this principle have a temperature resolution no better than a few degrees (Berthou and 
Jörgensen, 1990), making them impractical for biological applications requiring high precision. 
Fluorescence signal processing is greatly simplified if temperature information can be given as 
the ratio of two light intensities rather than requiring a time-resolved measurement. This is the 
basis for the fluorescence intensity ratio (FIR) principle. In order for this principle to apply, the 
ratio must be an inherent function of temperature alone, and the same ratio of optical signals 
must be conveyed down the fibre regardless of disruptions in transmission of light along the 
fibre  (Berthou and Jörgensen, 1990). These conditions are satisfied by the rare-earth ion 
erbium. The first condition is satisfied by the 2H11/12 and 
4S3/2 levels of erbium that fluoresce at 
approximately 520 and 550 nm respectively (Berthou and Jörgensen, 1990). This pair of 
excited levels are close enough to each other to be thermally linked, which allows the 
2H11/12 level to be populated by the 
4S3/2 level during thermal agitation (Fig. 1.7), therefore 
temperature can be expressed as a ratio of the two light intensities at approximately 520 and 
550 nm (Dos Santos et al., 1998, Berthou and Jörgensen, 1990, Maciel et al., 1995). The second 
condition is also satisfied here as fibre bends, and the fluctuations these cause to the spectral 
loss curve of the fibre, only amount to a shift in signal amplitude. The power ratio remains 
unaffected and therefore temperature information can still be discerned (Berthou and 
Jörgensen, 1990).  
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Figure 1.7: (a) Erbium and ytterbium energy level diagram detailing energy absorption required to reach 
higher energy excited states. (b) Example erbium ytterbium spectra for the two measured fluorescence signals. 
The two bands recorded to measure the fluorescence intensity are shaded in red and blue. Both low (23 °C, 
black) and high (39 °C, red) temperature emission spectra are shown, demonstrating the variation in the 
emission ratio of the two bands with changing temperature. Derived from Schartner and Monro (2014).  
Erbium doped temperature sensors based on this principle have been explored in the past. For 
example, Berthou and Jörgensen (1990) found an almost linear temperature dependence of 
fluorescence in optical fibres doped with 1% erbium under the excitation of a 488 nm argon 
laser. They also showed that co-doping the glass with a sensitizer, in this case ytterbium, 
dramatically reduced the excitation power requirements compared to erbium alone. Ytterbium 
ions (Yb3+) can be used as sensitisers due to their large absorption cross section compared to 
the weaker absorption of erbium ions (Er3+). This greatly reduces the excitation power required 
to generate a given fluorescence signal (Desirena et al., 2008, Jakutis et al., 2010, Schartner 
and Monro, 2014). This finding is important considering the increased cost, reduced lifetime, 
and practicality issues a source of high excitation power would present, as well as the hazard 
it would pose to living cells if used to perform sensing in biological tissue samples. Yb3+ 
absorbs the near-infrared (NIR) radiation of the laser at 980 nm and transfers this energy to the 
acceptor Er3+ according to the equation: 
Chapter 1 – Research Background 
 
Stefan Musolino, PhD Thesis 2019  35 
Yb3+(2F5/2) + Er
3+(4 I15/2) → Yb
3+(2F7/2) + Er
3+(4I11/2) (Desirena et al., 2008). 
As Er3+ relaxes to its ground state it releases this absorbed energy as green photons at 
approximately 524 nm and 547 nm (Schartner and Monro, 2014) (Fig. 1.7). As stated 
previously, the temperature of the host medium can be expressed as the ratio of these two light 
intensities. 
 1.8.4 Biomedical application of optical fibre temperature sensors 
Temperature is a key vital sign and a routinely monitored parameter in all clinical settings. 
Although the requirements of temperature sensors are application dependent, a range of 35-45 
°C with a resolution of 0.1 °C is required for the majority of applications (Teunissen et al., 
2011). As mentioned previously, optical fibre sensors can be employed to measure temperature 
when requiring a temperature sensor immune to EMI or when electrical insulation is required 
(Mignani and Baldini, 1996, Christensen, 1988) such as during magnetic resonance imaging 
(MRI) or radio frequency treatment (Christensen, 1988, Dziuda et al., 2013, Su et al., 2017, 
Correia et al., 2018). Also, thanks to their constitution, usually glass or polymer, they are not 
prone to temperature overestimation caused by light absorption and have low heat 
conductivity compared to conventional thermocouple probes (Schena et al., 2016). Although 
commercial optical fibre temperature sensors are readily available, there are few examples of 
their use in animals and humans in vivo (Schena et al., 2016). Samset et al. (2001) measured 
temperature distribution with multiplexed FBG sensors to validate 3D temperature maps during 
cryo-surgery in porcine livers (Samset et al., 2001). Yoo et al. (2010) proposed respiration 
sensors for respiratory monitoring during an MRI scan and reported two types of non-invasive 
sensor. The first, a nasal-cavity attached sensor capable of measuring temperature variation of 
air-flow, and the second, an abdomen-attached sensor capable of measuring abdominal 
circumference change (Yoo et al., 2010). Webb et al. (2000) performed in vivo trials with a 
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FBG temperature sensor on diseased livers and healthy kidneys in rabbits undergoing 
hyperthermia (Webb et al., 2000). A key advantage of biomedical temperature sensing using 
optical fibres is their potential for multiplexed sensing when combined with other optical 
sensing techniques. The combination of multiple sensors within the same network enables the 
measurement of multiple parameters within the one system without requiring the implantation 
of additional sensing equipment. Tosi et al (2016) described an optical fibre sensor for intra-
tissue pressure and temperature measurement in liver tissue undergoing laser ablation. Li et al 
(2018) described a miniaturized single-fibre-based imaging and sensing probe capable of 
simultaneous optical coherence tomography imaging and temperature sensing. Fajkus et al 
(2017) also described a multiplexed system for the measurement of body temperature, HR, and 
respiratory rate. The system was tested on 10 human volunteers and displayed good correlation 
with conventional measurement techniques. Although optical fibre sensors present numerous 
advantages over conventional technology, the crucial challenge for researchers in this field 
is to increase academic and clinician awareness about their ability to overcome the 
drawbacks related to the use of traditional electrical sensors. This could lead to their increased 
use in biomedical studies to investigate multiple parameters in locations where previously it 
may have been impossible or impractical to do so. Their implementation would also be a large 
improvement on conventional assays in many research areas, such as brain thermorecording 
during MDMA-induced hyperthermia using thermocouple electrodes. 
1.9  Current strategies for treatment of MDMA-induced hyperthermia 
The difficulty in treating MDMA-induced hyperthermia comes from the complex central and 
peripheral effects that the drug has on pathways involved in thermoregulation. MDMA 
deregulates heat accumulation in the brain by increasing the release of, and preventing the re-
uptake of key neurotransmitters (Colado et al., 1995, Green et al., 2004). The accumulation of 
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these neurotransmitters can lead to an increase in noradrenergic signalling that contributes to 
the peripheral effects of MDMA by affecting cutaneous vasoconstriction, blood flow, and 
tissue thermogenesis (Pedersen and Blessing, 2001, Docherty and Green, 2010). As mentioned 
previously, complications arising from MDMA-induced hyperthermia can be life-threatening. 
Pharmacological treatment strategies to manage this hyperthermic response have been studied 
extensively animal models (Kiyatkin et al., 2016, Mechan et al., 2002, Nash et al., 1988, 
Freezer et al., 2005, Anderson et al., 2011), however, these treatments have not been 
systematically evaluated in the emergency room setting as hyperthermic complications are 
relatively rare. However, placebo-controlled studies have been conducted, which can inform 
us of mechanisms underlying MDMA-induced hyperthermia in humans, and the effects of 
potential future pharmacological interventions. 
Surveys of drug-related emergency department admissions show that intravenous fluid 
replacement, and patient sedation with benzodiazepines are the most effective first response in 
patients presenting with acute drug-induced hyperthermia (Halpern et al., 2011). External 
cooling techniques such as fanning, icepacks, ice baths, and cooling blankets are also important 
for continued management of hyperthermia (Hall and Henry, 2006). The muscle relaxant drug 
dantrolene has also been used in extreme cases of hyperpyrexia (Grunau et al., 2010), however 
it does not work to inhibit the thermogenic effects of MDMA nor the pharmacological 
mechanisms of MDMA-induced hyperthermia in the brain (Rusyniak et al., 2004). Peripherally 
acting adrenergic receptor antagonists have proven to be useful in reversing increased 
temperatures induced by MDMA. Blockade of α-adrenoreceptors in human subjects was shown 
to reduce temperature, and blood pressure increases induced by MDMA (Hysek et al., 2013a). 
Furthermore, a combined α- and β- receptor blockade was also shown to reduce these MDMA-
induced increases in humans (Hysek et al., 2012, Hysek et al., 2013b), and these results were 
also found in experimental animals (Kiyatkin et al., 2016). Kiyatkin et al. (2016) also 
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demonstrated that drugs acting centrally, such as the 5-HT2A receptor antagonist clozapine, had 
greater hypothermic effects in the brain and body of rats when compared to peripherally acting 
adrenoreceptor antagonists (Kiyatkin et al., 2016). In humans, the centrally acting 5-HT2A 
receptor antagonist ketanserin reduced MDMA-induced increases in body temperature (Liechti 
et al., 2000b), similar to previous results reported in animals (Nash et al., 1988). Furthermore, 
pretreatment with the selective NA reuptake inhibitor reboxetine attenuated MDMA-induced 
increases in body temperature in humans (Hysek et al., 2011), and pre-clinical data has shown 
that D1 receptor antagonists could possibly contribute to the attenuation of MDMA-induced 
hyperthermia (Mechan et al., 2002), however this has not yet been evaluated in humans. 
Despite the wealth of human and animal data advocating the efficacy of both central and 
peripherally acting pharmacological interventions for MDMA-induced hyperthermia, there are 
some risks associated with their use (Liechti et al., 2000a, Hysek et al., 2010, Lange et al., 
1990), and many have not undergone testing in clinical trials. Considering this, the current 
pharmacological strategies for treatment of MDMA-induced hyperthermia are limited. 
Therefore, there is a clear need for a pharmacological intervention for attenuating MDMA-
induced hyperthermia in an emergency room setting. 
1.10  Minocycline 
 1.10.1 History of origins 
Since their discovery in the 1940’s, tetracyclines have undergone many molecular 
modifications to enhance their antibacterial activity, tissue absorption and half-life (Stirling et 
al., 2004). The antibiotic properties of tetracyclines were initially described in the late 1940’s, 
however more recently numerous studies have focused on their non-antibiotic properties as 
they have displayed a variety of biological actions independent of their antimicrobial activity. 
Minocycline (Fig. 1.8) is a second-generation tetracycline derivative with better 
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pharmacokinetic profile than first generation tetracyclines. When administered orally, it is 
rapidly and completely absorbed with a long half-life, good tissue penetration, and an almost 
complete bioavailability (Garrido‐Mesa et al., 2013, Klein and Cunha, 1995). Minocycline is a 
highly lipophilic molecule that can pass through the blood-brain barrier (Brogden et al., 1975) 
and accumulate in the cerebrospinal fluid (CSF) and CNS (Kielian et al., 2007), enabling its 
use to treat many CNS diseases (Wang et al., 2003, Yong et al., 2004). It has been shown to 
provide neuroprotection from a wide range of neurodegenerative diseases including brain 
ischemia (Yrjänheikki et al., 1998), spinal cord injury (Stirling et al., 2004), and dopamine 
neurotoxicity caused by 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) (Du et al., 2001). 
 
Figure 1.8: Chemical structure of minocycline and its parent, tetracycline. 
 1.10.2 Mechanisms of action of minocycline 
Neuroprotective effects provided by minocycline are known to be related to its antioxidant, 
anti-inflammatory, and inhibitory glutamatergic effects not unrelated to its well-known anti-
microbial properties (Dean et al., 2012). Minocycline causes an inhibition of microglial 
activation (Kim et al., 2009, Yrjänheikki et al., 1998, Dean et al., 2012) and release of 
subsequent cytotoxic substances. A high repeated dosing regimen of minocycline (90 mg/kg 
i.p. day 1, 45 mg/kg i.p. day 2-3) was shown to reduce IL-1β levels following traumatic brain 
injury (TBI) in mice (Homsi et al., 2009), and also in rats treated with MDMA (12.5 mg/kg, 
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i.p.) (Orio et al., 2010). Minocycline also reduces prostaglandin-E2 (PGE2) and inhibits cyclo-
oxygenase-2 (COX-2) in a dose-dependent manner within murine microglia (Kim et al., 2004). 
It has also been shown to reduce prostaglandin-F2α (PGF-2α) and PGE2 production induced by 
lipopolysaccharide (LPS) in primary rat microglial cells via down-regulation of microsomal 
prostaglandin-E synthase (mPGES-1) (Silva Bastos et al., 2011). Minocycline administration 
reduces TNF-α levels in the brain following administration of 3-nitropropionic acid in rats 
(Ahuja et al., 2008, Levkovitz et al., 2010). These neuroinflammatory markers have been 
previously linked to subsequent neurotoxicity of monoamine pathways in the brain of animals 
(Orio et al., 2010). There is also evidence to support the role of reduced glutamate 
excitotoxicity, reduced oxidative stress, and augmented neurogenesis in the mechanisms of 
action of minocycline (Fig. 1.9) (Dean et al., 2012). Minocycline’s protective neuro-anti-
inflammatory effects, as well as its direct effects within monoamine systems in the brain, have 
been described in both animal and human models of illegal drug use (Zhang et al., 2006, Orio 
et al., 2010, Sofuoglu et al., 2011). 
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Figure 1.9: Proposed mechanisms of action of minocycline, including reduced glutamate excitotoxicity, 
inflammation, oxidative stress and augmented neurogenesis, targeted by minocycline. Derived from Dean et al. 
(2012). 
1.10.3 Minocycline and amphetamines 
Minocycline readily crosses the blood–brain barrier and its neuro-anti-inflammatory effects 
significantly impact 5-HT, DA, and glutamate transmission in the brain. In preclinical studies, 
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minocycline attenuates the development of behavioural sensitization to amphetamines 
(Kofman et al., 1990, Zhang et al., 2006), as well as the release of dopamine induced by 
amphetamines in the brain (Zhang et al., 2006). Furthermore, minocycline attenuates the 
reduction of dopamine transporters (DATs) caused by repeated amphetamine administration in 
the brains of monkeys (Hashimoto et al., 2007). These inhibitory effects are possibly mediated 
by minocycline’s glutamatergic actions in the brain as minocycline has been shown to block 
behavioural responses mediated by NMDA-type glutamate receptors in both mice (Fujita et al., 
2008) and rats (Levkovitz et al., 2007, Munzar et al., 2002). Minocycline reduces glutamate 
release in hippocampal neurons of rats (González et al., 2007) and increases phosphorylation 
and surface expression of GluR1-type AMPA receptor subunits in mouse striatal neurons 
(Imbesi et al., 2008). In humans, minocycline attenuates the subjective rewarding effects of 
dextroamphetamine (DAMP), and reduces cortisol levels following DAMP or placebo 
administration in healthy volunteers (Sofuoglu et al., 2011). It has also been shown to 
improve responses to the sustained attention to response test (SART) in humans (Sofuoglu et 
al., 2011), a result supporting its previously demonstrated cognition-enhancing effects in 
animals (Fujita et al., 2008, Levkovitz et al., 2007, Levkovitz et al., 2010). 
Minocycline offers neuroprotection in animal models of MDMA-induced neurotoxicity. Orio 
et al (2010) demonstrated that a twice daily repeated administration of minocycline over two 
days (45 mg/kg i.p. day 1, and 90 mg/kg i.p. day 2) prevented MDMA-induced NFκB 
activation, IL-1β release and microglial activation in the frontal cortex and prevented 5-HT 
neurotoxicity 7 days later. Similarly, Zhang et al (2006) showed that minocycline (40 mg/kg) 
attenuated the reduction of 5-HT and DA as well as the density of 5-HTT and DAT in the 
striatum after the repeated administration of MDMA. They also showed that minocycline 
attenuated the increase of activated microglia in the hippocampus and striatum (Zhang et al., 
2006). Although these studies demonstrated that minocycline administration impacts 
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microglial activation, pro-inflammatory cytokine release and monoamine release in the brain, 
they also showed these changes had no significant effect on MDMA-induced hyperthermia. A 
two-day dosing regimen of minocycline (45 mg/kg first day and 90 mg/kg second day) had no 
effect on MDMA-induced hyperthermia causing no significant decrease in rat core body 
temperature (Orio et al., 2010). Similar results were obtained by Zhang et al (2006) who found 
that MDMA produced a significant hyperthermic response in core body temperature (+2.5 °C) 
that was not attenuated by minocycline. These results suggest that the neuroprotective effects 
of minocycline against MDMA-induced neurotoxicity are not due to a reduction in the body 
temperature that has been previously shown to exacerbate MDMA-induced neurotoxicity 
(Gordon et al., 1991, Broening et al., 1995, Brown and Kiyatkin, 2004). In contrast, Anderson 
et al (2011) showed that a 3 day dosing regimen of minocycline (50 mg/kg) was effective in 
attenuating MDMA-induced hyperthermia in Sprague-Dawley rats, whereas both one and two-
day dosing regimens did not achieve this effect (Anderson et al., 2011). They also demonstrated 
that minocycline had no significant effect on brain or blood concentrations of MDMA 
(Anderson et al., 2011). These results indicate that minocycline’s hyperthermia-attenuating 
effects are a time-dependent process requiring more than 48 h to achieve maximum effects. 
1.11  Research Aims 
1.11.1 Optical fibre temperature sensor development 
The aim of this work was to develop an optical fibre-based point temperature sensor suitable 
for use in freely-moving animals. Previous studies investigating MDMA-induced brain 
hyperthermia have utilised thermocouple electrodes, which lack the advantages provided by 
light-based sensing. Practical use of previously developed optical fibre fluorescence 
temperature sensors in vivo was limited due to the use of bulk optics, and large benchtop 
spectrometers for analysis of changes in the optical signal. Other limitations included poor 
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probe durability, readout instability caused by vibration and environmental factors, as well as 
long-term measurement errors. In this work many systematic tests were performed to isolate 
the source of measurement instabilities, before making changes to both the optical 
configuration and sensor material make-up in accordance with these findings.  
1.11.2 Publication 1: “Portable optical fibre probe for in vivo brain temperature 
 measurements” (Biomedical Optics Express, 2016) 
The aim of this study was to demonstrate proof-of-principle of a portable rare-earth doped 
optical fibre point temperature sensor in the brains of freely-moving animals. This work was a 
direct follow-up to our previous developmental work on an optical fibre point temperature 
sensor based on rare-earth thermometry (Schartner and Monro, 2014). In this study, brain 
temperature was recorded in saline treated rats for an extended time period to ensure that the 
sensor could accurately record brain temperature in vivo for the entire experimental duration 
post-drug administration. Optical fibre brain temperature measurements were also combined 
with body temperature monitoring using radiotelemetry with the intention of utilising this 
combined technology in future studies to investigate the thermoregulatory, and physiological 
effects of MDMA and minocycline in freely-moving rats. 
1.11.3 Publication 2: “Improved method for optical fibre temperature probe 
 implantation in brains of free-moving rats” (Journal of Neuroscience Methods, 
 2019) 
There were two primary aims of this study. The first was to develop an improved method for 
optical fibre sensor implantation in freely-moving animals using conventional microdialysis 
materials. The second was to determine the acute temperature effects of MDMA in the rat brain 
using this improved optical fibre probe. This work was an extension of previous probe 
development efforts that developed an optical fibre point temperature sensor for brain 
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temperature recording in awake, freely-moving rats. A limitation of the previous method was 
the high risk of probe breakage prior to and during experimentation, particularly when the 
animal was administered MDMA, resulting in loss of time and resources spent replacing the 
sensor. Standard microdialysis probe materials were used in the revised probe structure to allow 
the implantation and removal of the fibre as a single piece. This was done to permit multiple 
insertion and removal procedures for each probe as well as high throughput animal 
experiments. This was also done to make the surgical implantation and handling of the optical 
fibre sensor as similar as possible to that of conventional microdialysis probes. The improved 
sensor was tested in MDMA-treated animals at high ambient temperature to investigate the 
hyperthermic effects of MDMA in the brain. 
1.11.4 Publication 3: “Minocycline attenuates 3,4-Methylenedioxymethamphetamine 
 induced brain hyperthermia (Accepted, European Journal of Pharmacology, 
2019) 
The aims of this study were three-fold. The first was to examine and compare the 
thermoregulatory and physiological effects of MDMA at both normal and high ambient 
temperature. The second aim was to examine the thermoregulatory and physiological effects 
of minocycline in response to MDMA-challenge at high ambient temperature. The third aim 
was to determine the relationship between brain and body temperature changes induced by 
minocycline and MDMA. This work using minocycline was an extension of the previous paper 
that demonstrated that MDMA induced a significant hyperthermic response in the brain at high 
ambient temperature.  Minocycline has been shown to attenuate MDMA-induced hyperthermia 
in the body. I considered it important to understand its hyperthermia-attenuating effects in the 
brain, as well as the relationship between brain and body temperature change as the brain is the 
most temperature-sensitive organ in the body, and the most harmful effects of acute MDMA 
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administration relate to its modulation of neural activity in temperature regulatory circuits. In 
addition to this, radiotelemetry was used to measure the effects of minocycline on HR and 
LMA to gain a better understanding of its potential physiological and pharmacological 
mechanisms of action.
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Chapter 2 – Optical fibre temperature sensor development 
2.1  Introduction 
Monitoring of physiological parameters such as temperature within the body is a process that 
requires purpose-built tools in order to achieve accurate and specific monitoring outcomes, 
especially in areas such as the brain that performs a critical role in controlling body 
temperature. Currently, experimental brain temperature monitoring in vivo is typically 
performed utilising thermocouple electrodes capable of region-specific brain temperature 
measurement (Kiyatkin et al., 2016, Kiyatkin et al., 2014, Brown and Kiyatkin, 2004). 
However, optical fibre sensors present an alternative to many conventional techniques for the 
real-time in vivo monitoring of many physiological parameters. Their small size and inert glass 
composition make them suitable for minimally invasive implantation in small brain regions, 
and their ability to provide multiplexed sensing allows for the probing of many different 
physiological processes within the one system. Despite this, many of the different techniques 
previously used to perform temperature sensing utilizing optical fibres are unsuitable for 
region-specific in vivo monitoring in the brain due to issues with their resolution (Rao, 1997), 
long-fibre length requirements (Lee and Nishii, 1998), and sensitivity to changes in 
environmental conditions (Guan et al., 2006). 
As previously discussed in section 1.8.3, one promising alternative method for temperature 
measurement utilising optical fibres involves rare-earth absorption and fluorescence 
monitoring. However, previous methods utilising upconversion emission as a temperature 
indicator have often been based on bulk glass samples (Chen et al., 2015), uniformly-doped 
optical fibres (Da Silva et al., 2000, Dos Santos et al., 1999) or doped microspheres (Cai 
and Xu, 2003). While these doped sensors can carry certain advantages, like the previous 
methods they lack the ability to perform measurements with a high spatial precision limiting 
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their in vivo application where spatially precise measurements are required. This limitation 
led to the recent development of a high spatial resolution fibre-tip sensor for localised 
temperature measurement based on rare-earth thermometry (Schartner and Monro, 2014). 
The point temperature sensors described here (Schartner and Monro, 2014) were fabricated 
by briefly immersing the tips of silica multi-mode fibres into Er:Yb co-doped tellurite glass, 
which greatly minimized the size of the temperature sensitive region of the probe compared 
to uniformly doped fibres or bulk glass samples. In vitro experiments using this probe 
displayed a good correlation between reference temperatures and the fluorescence ratio of 
the Er:Yb doped samples for the duration of measurements with the measured change in 
fluorescence ratio approximated as linear with a short-term resolution of <0.1 °C (Fig. 2.1). 
However, the long-term accuracy of this sensor was approximated at 0.1-0.3 °C due to 
stability drift associated with long-term measurements. These results demonstrated a new 
approach to localised temperature measurement based on a probe at the tip of an optical 
fibre (Schartner and Monro, 2014). The localised temperature sensitive region in addition to 
the minimal excitation power requirements of the probe suggested it was suitable for in vivo 
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Figure 2.1: A: Erbium ytterbium-doped multi-mode fibre response with a co-located reference resistance 
temperature detector (RTD) inside an incubator. B: Linear regression of fluorescence ratio vs. reference 
temperature for increasing temperature. Derived from Schartner and Monro (2014). 
As a part of my honours research, we attempted to utilise this sensor for brain temperature 
measurement in live animals, however, the transition of this sensor from in vitro to in vivo 
sampling presented numerous challenges. Similar to in vitro results of the previous study, long-
term drift in probe FIR readings, and increasing levels of noise were apparent in the later stages 
of in vivo brain temperature recording (Fig. 2.2). These increased levels of noise and long-
term drift resulted in observed brain temperature fluctuations of between approximately 1.5 
to 2 °C towards the end of each animal experiment. The unsheathed glass fibres were also 
extremely susceptible to twisting and breakage during periods of increased animal movement 
resulting in the loss of the sensor and premature termination of experiments. Prior to breakage, 
fibre twisting was also seen to cause large observed temperature artefacts as the fibre was bent 
too close to its critical bend radius resulting in reductions in light transmission to the 
spectrometer (Fig 2.3). 
A B 
Chapter 2 – Optical fibre temperature sensor development 
 
Stefan Musolino, PhD Thesis 2019  50 
 
Figure 2.2: A: Brain temperature readout obtained from fibre optic probe implanted in rat brain. Subject was pre-
treated with saline during the recovery period mimicking a therapeutic drug pretreatment schedule and received 
MDMA (10 mg/kg, i.p.) at approximately 49-h. B: Final 2 hours of the experiment. Probe breakage occurred 


































Figure 2.3: FIR readout obtained from fibre optic temperature sensor implanted in rat brain. Subject was pre-
treated with saline during the recovery period mimicking a therapeutic drug pretreatment schedule. * depicts time 
points where the fibre was twisted excessively causing the detector to detect a false FIR drop. 
Based on these in vivo experiments, the temperature sensor in this configuration was deemed 
unsuitable for in vivo use in freely-moving animals. The dramatic changes in observed 
temperature caused by animal movement, fibre bending, long-term drift, and increased noise 
levels, resulted in very low probe stability, well outside of the target resolution of 0.1 °C that 
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would make it suitable for biological applications. This paired with its low durability and 
susceptibility to breakage during animal movement made the current fibre structure and 
optical configuration unsuitable for in vivo sampling. 
Considering these limitations, the first aim of this PhD project was to further develop the 
stability and durability of this optical fibre point temperature sensor to increase its suitability 
for in vivo use. We also aimed to adapt the configuration to a more portable setup to facilitate 
its deployment outside of a conventional optics laboratory. This was achieved through many 
sequential changes to the probe structure and sensing configuration following the identification 
of the limiting features of the setup. This step-by-step developmental process is described in 
detail below. 
2.2 Durability improvements 
2.2.1 Signal bending-loss – High Numerical Aperture fibre 
As mentioned previously, early iterations of the optical fibre temperature sensor suffered 
drawbacks related to its use in freely-moving animals. Previous in vivo experiments 
demonstrated that probes fabricated with standard single-mode (SM) fibres were susceptible to 
false FIR changes caused by animal movement-induced fibre bending (Fig. 2.3). Bending 
modifies the guiding properties of optical fibres causing loss increasingly as the fibre is bent 
closer to its critical bend radius (Jay, 2010). Light can “leak out” of the fibre as it bends, and 
as the bend becomes more acute, more light leaks out. In our application, this reduction in 
signal due to bending expressed itself as a shift in observed temperature. Although the FIR 
method is usually independent of factors such as bending and power change, this was not 
exactly the case in our application as the changes we measured were relatively minor and only 
over a small temperature range. This therefore increased the sensitivity of the temperature 
sensor to bending losses and changes in power with only a 3-4% change in FIR needed to 
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amount to a significant 0.5 °C change in observed temperature at 37 °C. This magnitude of 
temperature discrepancy was well outside of the probes’ required resolution of 0.1 °C and 
unacceptable for biological measurements as even small observed changes in temperature are 
viewed as significant, especially within the brain. In an attempt to remedy this, we used high 
numerical aperture fibre during subsequent probe fabrications and tested its ability to reduce 
the effects of bend-loss in subsequent in vitro experiments. 
The numerical aperture of an optical fibre is a number that describes the range of angles prior 
to its critical angle at which incoming light can be totally reflected into the fibre core. If the 
light exceeds this critical angle outside of its numerical aperture, it undergoes refraction outside 
of the fibre core and into the cladding. Optical fibres with a high numerical aperture have an 
increased acceptance angle of light entering the fibre and thus allow the transmission of light 
at a more acute angle when compared to ordinary multi-mode (MM) or SM fibres and are thus 
less susceptible to bend-induced signal loss (Harris and Castle, 1986). A standard single mode 
fibre has a numerical aperture of approximately 0.13. To reduce the effects of bend-loss on our 
FIR data, we tested probes fabricated with commercially available ultra-high numerical 
aperture (UHNA) fibre with a NA 0.35. The high numerical aperture optical fibre probe was 
placed inside an incubator maintained at approximately 39 °C. Light from the laser was 
transmitted through an unbent fibre to establish control temperature values. The fibre was then 
bent around a mandrel of 8 to 16 mm in diameter a total of 5 full turns while kept under slight 
tension to remove slack. Temperature data was recorded from the probe whilst under varying 
bend intensities (Fig. 2.4). 
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Figure 2.4: A: Photo of the bend-loss measurement setup; the variable (the bend diameter) is indicated in red. B: 
Temperature recorded by optical fibre probe at various bend diameters compared to unbent fibre temperature of 
39 °C. 
These experiments demonstrated that high numerical aperture fibre had a critical bend radius 
of approximately 8 mm. Slight changes in observed temperature were observed at bend 
diameters ranging between 10 to 16 mm however these changes were deemed insignificant. At 
an 8mm bend diameter however, a significant deviation was present with observed 
temperatures reaching approximately 42 °C, 3 °C higher than the bath temperature indicating 
significant bend-loss. Although these results showed a significant change in observed 
temperature change at an 8 mm bend diameter, this change was significantly reduced compared 
to previous in vivo experiments using SM fibres (Fig. 2.3) that displayed a much higher 
influence of fibre bending on observed FIR values. Although the use of high numerical aperture 
fibre dramatically reduced the probes’ susceptibility to bend-loss, it did not eliminate it entirely, 
nor did not remove the greater issue of stability drift over the course of long-term measurements 
(Fig. 2.5). Considering this, high numerical aperture fibre was unsuitable for use during probe 
fabrication due to the long recording and recovery associated with our in vivo experimental 
protocol. However, following these experiments subsequent mechanical improvements were 
made to fabrication materials and methods to increase the probes durability during in vivo 
experimentation, and reduce its susceptibility to coiling caused by increased animal movement. 
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Figure 2.5: UHNA erbium:ytterbium doped optical fibre temperature sensor FIR response with co-located 
RTD. Probe measurements were performed inside an incubator maintained at a constant temperature.  
2.2.2 Animal movement-induced fibre coiling and breakage - Splice procedure 
One of the main fabrication procedures altered from the original probe fabrication methods was 
the probe splicing technique. The original probe fabrication technique used a Fujikura arc 
splicer FSM-100 (Fujikura Ltd, Tokyo, Japan) to splice the front length of fibre containing the 
probe tip with a separate fibre length containing the connectorised patch cable to allow easy 
integration of the probe with the measurement equipment (Fig. 2.6). To fabricate the front 
portion of this probe, one meter of fibre was cut and the front end of the fibre was inserted into 
a needle cut to a length of 4 mm, cleaved, and then glued inside the needle body with 
approximately 2 mm of fibre protruding from the end to act as the probe tip. 15 mm of polymer 
coating was stripped from the back end of this fibre as well as from a separate fibre length 
containing the connectorised patch cable. Both stripped portions of the fibres were cleaned with 
isopropanol and set in a fibre holder so their ends could be cleaved using a high precision 
cleaver (Fujikura CT-30). The fibre probe was spliced together with the patch cable using the 
arc splicer and the splice location protected using heat-shrink tubing (Fig. 2.6). 
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Figure 2.6: Diagram of fibre probe and patch cable fibre. A. Pre-splice. B. Post-splice. 
The arc-splicer automated splice routine calculates the estimated loss from a splice, which in 
most cases is a negligible value, as seen in Fig, 2.7A. However, in some cases, hotspot bubbles 
and misalignment occurred during splicing procedures due to contaminated fibre end-faces, 
poor fibre cleavage, and slippage during end-face heating and fibre push (Fig. 2.7B/C). When 
this occurred, it often resulted in higher estimated splice loss. This required the splice to be 
broken, and the splice process repeated until negligible loss values were acquired. This required 
re-cleaving and re-splicing the fibre which resulted in shorter fibre lengths, and longer 
fabrication times. A longer fibre lead gives more room for the fibre to coil during animal 
movement, and thus longer fibre lengths are less susceptible to coiling-induced breakage. 
Continued re-splicing of the probe often resulted in significantly shorter fibre lengths, and this 
made the probe much more susceptible to bending and eventually breakage via excessive 
coiling. 
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Figure 2.7: A. Arc splicer image of fibre before splicing. B. Arc splicer image of fibre after splicing with 
estimation and error data. C. Arc splicer image sowing bubble present at splice location that can occur due to 
contaminated fibre end-face or poor fibre cleavage. D. Misaligned fibre due to slippage during fibre push prior to 
splicing. 
In addition to this, the heat-shrink tubing protecting the exposed splice location was the primary 
location for fibre twisting and breakage during animal movement (Fig. 2.8). The heat-shrink 
protector impeded the ability of the fibre to coil during in vivo experiments, thus the probe 
broke on several occasions at either side of tubing protecting the splice location. To remedy 
this, the temperature sensor was fabricated at the front end of a 2 m length of continuous cable 
with a more robust 900 μm outer cladding that included the connectorised patch cable. This 
removed the necessity for splicing that was present in the original temperature sensor 
fabrication method. The removal of splicing significantly increased the average length each 
probe which aided its ability to coil during animal movement and removed the splice location 
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which drastically reduced the probes susceptibility to breakage. The use of this altered probe 
fabrication method dramatically decreased the number of probe breakages that occurred during 
follow up in vivo trials and allowed for increased experimental throughput. 
 
Figure 2.8: Image of optical fibre twisted around heat-shrink tubing protecting the splice location.  
2.3 Long-term stability improvements 
As mentioned previously, the original optical configurations (Fig. 2.9) were sensitive to 
environmental changes, and stability drift over the course of long-term measurements, which 
affected the long-term accuracy of system (Fig 2.10). Several changes were made to the 
equipment used in the optical set-up to remedy these stability issues. Additional changes were 
also made in order to reduce the benchtop footprint of the optical setup in the restricted 
laboratory space and increase its portability. This was mainly achieved by removing any bulk 
and free-space optical equipment that was present in the original optical configuration, thus 
reducing the size of the set-up and removing the need for the alignment of any optical 
components. 
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Figure 2.9: Previous bulk optics configuration for optical fibre temperature measurements from Schartner and 
Monro (2014). 
 
Figure 2.10: A. Erbium:ytterbium doped optical fibre temperature sensor FIR response with co-located RTD. 
Probe measurements were performed inside an incubator maintained at a constant temperature. Long-term 
drift of the FIR readings was observed during the later stages of the experiment. Periodic oscillations caused 
by shifts in lab ambient temperature were also observed throughout the duration of the experiment. B. Diagram 
of components of optical configuration. SM components of the sensing configuration are highlighted in red.  
2.3.1 Need for alignment - Short-pass filter 
One of the first changes made to the configuration involved the short-pass filter. Like the 
previous configuration, the output port of the fibre coupler was passed through a short-pass 
filter to remove the residual pump light. However, in the new set-up this filter was situated 
inside of a lens tube in order to remove the need for its alignment. As previously mentioned, 
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many changes were made to the optical configuration to reduce its size, increase its portability, 
and facilitate its use in a medical research laboratory. The removal of the majority of the bulk 
optics, and any equipment that required careful alignment was crucial for the probes’ 
deployment in our laboratory, which lacked access to optical tables that would normally enable 
the alignment of these components with mounting holes and provide a vibration dampening 
surface (Fig. 2.11).  
 
Figure 2.11: Labelled photograph of the components of the portable optical fibre temperature sensing 
configuration. Removal of most bulk optics and aligned equipment allows the configuration’s deployment outside 
a conventional optics laboratory.  
2.3.2 Laser signal variability - Excitation source and isolator 
The optical configuration of the original sensor used a 980 nm pigtailed SM laser diode as the 
source of excitation for the Er:Yb co-doped fibre tips (Schartner and Monro, 2014). The 
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continued use of a 980 nm laser source and two-photon upconversion in the improved optical 
configuration was advantageous compared to direct excitation of ions at lower wavelengths as 
this minimised the potential for local heating at the end face of the fibre tip. This end-face 
heating may have affected the validity of temperature data gathered and damaged the cells 
surrounding the probe tip in this area. 
Unlike the original configuration, we also introduced an isolator into the system to reduce 
signal variability from the laser. This significantly reduced back-reflected light and prevented 
it being coupled back into the laser diode. If this were to occur, it would cause instabilities in 
signal emission from the laser which could also potentially influence the accuracy of 
temperature measurements. 
Although a 980 nm laser was maintained as the excitation source, initial systematic tests 
revealed the pigtailed SM diode to be the source of some stability issues with the new portable 
set-up. In vitro tests revealed that ratiometric temperature was susceptible to changes in 
laboratory ambient temperature despite the probe being located within a temperature-controlled 
incubator (Fig 2.10). Further tests established that these periodic oscillations caused by ambient 
temperature changes correlated with changes in laser voltage (Fig 2.12). 
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Figure 2.12: SM configuration Erbium:ytterbium doped optical fibre temperature sensor temperature FIR and 
laser voltage response with co-located RTD. Probe measurements were performed inside an incubator 
maintained at a constant temperature.  
To remedy this issue, the original SM diode was replaced with an equivalent polarisation 
maintaining (PM) diode and a similar in vitro experiment was conducted (Fig. 2.13). Our 
results showed that the configuration with the PM diode was less susceptible to environmental 
changes as no fluctuations in probe observed temperature occurred in response to changes in 
laboratory ambient temperature. However, these results also showed that the PM diode did not 
improve the long-term stability of the measurements as FIR readings still showed increasing 
drift away from temperature values towards the end of the experiment This remaining 
instability of long-term measurements suggested that the cause of instability in the system 
could be associated with drift in the polarisation of light through the coupler and variance in 
the returned fluorescence signal over time. Further changes to the system were therefore 
required to remove these long-term stability issues. 
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Figure 2.13: A. Optical fibre temperature sensor FIR response with co-located RTD. Probe recording was 
performed inside an incubator with temperatures cycled from high-low over the duration of the measurements. 
B. Diagram of components of optical configuration. SM components of the sensing configuration are 
highlighted in red; PM components are highlighted in green. 
2.3.3 Long-term stability drift - Coupler changes 
In the original probe configuration used by Schartner and Monro (2014), light that passed from 
the probe tip through the fibre was coupled into a spectrometer for spectral analysis using a 
SM coupler. The coupler is a key component required for high-precision measurements using 
fluorescence-based optical fibre sensors. If coupling of laser light, or returned fluorescence 
signal varies over time, then the collected signal becomes unreliable, which leads to errors in 
the measurement. The updated portable configuration also used a standard SM coupler, and as 
we have already shown, measurements conducted with this configuration were affected by 
long-term stability drift (Fig. 2.10) even when employed with a PM diode (Fig 2.13). To 
remedy this issue, we experimented with replacing this SM coupler with an equivalent PM 
fibre coupler. PM fibre is a type of SM optical fibre in which linearly polarized light entering 
the fibre maintains its polarisation as it propagates through and then exits the fibre. Unlike in 
standard SM optical fibres, PM fibre prevents crosstalk between vertical and horizontal 
Chapter 2 – Optical fibre temperature sensor development 
 
Stefan Musolino, PhD Thesis 2019  63 
polarisation modes travelling within the fibre as a result of bending and random fibre 
birefringence. This prevents changes to the output polarisation state of light travelling within 
the fibre over time, and therefore prevents long-term inaccuracies in gathered data. The coupler 
we tested was a 99:1 PM splitter with the probe connected to 1% output of the splitter. The 
original configuration used a dichroic mirror for this application (Fig. 2.9); however, this 
required the configuration to contain a free-space optics sections which required alignment, 
drifted with changes in environmental temperature, and was non-conducive to the increasing 
portability of the set-up. Similar to previous in vitro tests, the temperature sensor was co-
located in a temperature-controlled incubator with an RTD and temperatures recorded for the 
duration of the experiment (Fig. 2.14). Results of this test demonstrated that use of the PM 
coupler in addition to the PM diode still did not aid in improving long-term stability of the 
measurements compared to our previous results using SM couplers. Significant separation was 
still present between FIR and temperature readings towards later hours of the experiment and 
this drift equated to observed temperature differences of approximately 1 °C away from real 
temperature values. This differential was unacceptable for in vivo brain temperature 
measurements and therefore one final change was made to the sensing set-up to ensure the 
long-term accuracy of the system.      
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Figure 2.14: A. Optical fibre temperature sensor FIR response with co-located RTD. Probe measurements 
were performed inside a temperature-controlled incubator. B. Diagram of components of optical 
configuration. SM components of the sensing configuration are highlighted in red; PM components are 
highlighted in green. 
2.3.4 Removing long-term polarisation drift - PM fibre 
As mentioned previously, the original probe configuration (Schartner and Monro, 2014) 
utilised temperature sensors fabricated with multimode fibres to perform temperature 
measurements in vitro. Although trials using these temperature sensors showed a good 
correlation between the measured temperature and the fluorescence ratio (Fig. 2.1), a slight 
separation between FIR readout and measured temperature occurred over the course of long-
term measurements. This separation was also observed when using standard SM fibres as 
previously demonstrated in all of our in vitro fibre tests. In principle, use of a PM diode and 
coupler in this configuration could provide stable long-term measurements and preserve 
polarisation of light without PM fibre provided the SM fibre displayed a completely 
symmetrical design free from imperfections with no influence of fibre bending (Gordon and 
Kogelnik, 2000). However, fibre imperfections permeate nearly all optical fibres making some 
amount of birefringence unavoidable and this can affect the polarisation state of light along the 
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fibre length over time and lead to measurement inaccuracies (Gordon and Kogelnik, 2000).  
Considering stability improvements provided by inclusion of a PM diode and coupler, we 
decided to switch to an all PM portable configuration, which employed use of PM fibre as 
opposed to MM or SM fibre during probe fabrication (Fig. 2.15). 
 
Figure 2.15: Cross-section of 3 different types of optical fibre. 
To test the impacts of fabricating temperature sensors using PM fibre, the PM fibre temperature 
sensor was co-located in a temperature-controlled incubator with an RTD and temperatures 
recorded for the duration of the experiment (Fig. 2.16). 
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Figure 2.16: A. All PM configuration erbium:ytterbium doped optical fibre temperature sensor FIR response 
with co-located RTD. Probe measurements were performed inside a temperature-controlled incubator. B. 
Diagram of components of optical configuration. PM components of the sensing configuration are highlighted 
in green. 
Results from this test clearly demonstrated the increased stability in long-term measurements 
provided by the all-PM configuration compared to previous configurations using MM, UHNA 
or SM fibre types. At no point during the recording were probe FIR readings significantly 
separated from recorded RTD temperature, even during later periods of the experiment where 
stability drift was previously seen to be at its peak. Using the all-PM configuration, the 
measured change in fluorescence ratio could be approximated as linear over the biologically 
relevant range with an R2 of 0.998 (Fig 2.17) with no drift from the reference values occurring 
over the course of the long-term measurement.  
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Figure 2.17: Fluorescence ratio vs. temperature, R2 = 0.999 over the biologically relevant range. 
2.4 Conclusions 
This work has demonstrated that changes made to the original optical fibre temperature sensing 
configuration and probe fabrication method were successful in improving the probes’ durability 
and readout stability during long-term experiments when deployed in the portable sensing 
configuration. However, this developmental work in addition to our previous experiments 
using optical fibre temperature sensors has demonstrated that although advantageous, 
numerous difficulties exist when trying to deploy these optical systems within a medical 
research laboratory for in vivo sensing applications.  
The main issue of previous temperature sensing configurations was their sensitivity to 
environmental changes, and the measurement instabilities associated with use during long-term 
experiments. Our in vitro experiments demonstrated that the SM diode used in prior 
temperature sensing configurations was sensitive to changes in ambient temperature resulting 
in observed temperature artefacts caused by oscillations in laser voltage. In addition to this, 
they revealed the SM coupler and SM fibre to be a source of long-term term measurement 
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inaccuracy due to polarisation drift within the fibre.  We demonstrated that switching to an all-
PM configuration significantly increased long-term stability of FIR recordings and removed its 
susceptibility to environmental changes compared to configurations using SM equipment or 
MM fibres. Therefore, the use of PM fibre was a necessity in this application in order to 
maintain accurate FIR readings for the duration of each experiment. 
Probe durability was another issue associated with previous temperature sensing configurations 
as previous probes were susceptible to temperature artefacts caused by signal bend-loss and 
breakage during animal movement-induced fibre coiling. This vulnerability was reduced by 
removing the splice procedure and exposed splice location, which was the site of breakage in 
many probes, as well as increasing the thickness of the fibres’ outer cladding. Removal of the 
splice procedure significantly increased the average length of each probe, which aided its 
ability to coil without significant signal loss or probe breakage during in vivo experimentation. 
Although our in vitro results also demonstrated that UHNA fibre was effective in reducing 
effects of fibre bending on signal loss, it was shown to be non-conducive to increasing long-
term stability of the configuration, which was only later accomplished using PM fibre. Use of 
PM fibre in the finalised configuration limited options available for increasing sturdiness of 
the temperature sensor. This was due to it’s incompatibility with much of the commercially 
available equipment, such as rotation mounts and rotating connectors used to reduce the effects 
of fibre bending on acquired data. Although this equipment has its own issues associated with 
its use, such as variations in light transmission of up to 1 dB during fibre rotation that could 
lead to changes in observed temperature, it is also incompatible with the small 5 μm cores 
within our PM fibre sensor. Usage of these rotators in our configuration would require use of 
larger core MM fibres during probe fabrication to ensure their compatibility with our system, 
which would affect long-term system stability as we’ve already demonstrated, and also 
possibly introduce additional issues associated with MM fibres (Mehta et al., 2012). Our work 
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therefore employed a focus on SM, and later PM fibres, where these potential problems 
associated with MM fibres and fibre optic rotators were not applicable. Although the final 
changes made to increase probe durability were relatively minor and purely structural, they 
significantly increased sturdiness of the fibre without compromising the long-term stability 
provided by the all-PM configuration. 
Although advantageous in many aspects, optical fibre sensors face commercial competition 
from already well-established sensing technologies, which limits their use in many biomedical 
studies. To appeal to users accustomed to these traditional sensing methods, optical sensing 
systems should be more readily available in the forms of complete systems that are suitable for 
use outside of a conventional optics laboratory. To this end, changes were made to our 
temperature sensing configuration to comply with these requirements, such as the removal of 
bulk optics, and the use of equipment that required zero alignment. Not only did this improve 
the overall robustness of the setup and decrease its benchtop footprint, but also facilitated its 
deployment within our medical research laboratory where mounting and precision alignment 
using optical tables was not possible. Our results demonstrated that the finalised probe was 
able to perform stable long-term measurements in vitro, which were in agreeance with 
concurrent measurements of temperature. Although there were many issues associated with the 
initial development of this portable optical fibre temperature sensor, we believe the major 
issues associated with its in vivo use were minimised, and that its current form is more suitable 
for use in vivo. 
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Chapter 3 – Publication 1  
Musolino, S., Schartner, E.P., Tsiminis, G., Salem, A., Monro, T.M. and Hutchinson, M.R., 
2016. Portable optical fibre probe for in vivo brain temperature measurements. Biomedical 
optics express, 7(8), pp.3069-3077. 
The work performed in this paper aimed at successfully demonstrating proof-of-concept for a 
portable optical fibre-tip sensor capable of recording brain temperature in vivo. We describe a 
simple fabrication method that allowed for rapid fabrication of probes with no requirement for 
post-processing. Coating only the fibre tip as opposed to uniformly doping the fibre allowed 
for the sensing area to be spatially localized to a thin region directly in front of the core of the 
fibre. The rationale for this was to minimize the temperature sensitive area of the probe to allow 
brain thermorecording with a higher spatial precision compared to other optical fibre 
temperature sensing techniques. We use this probe to perform brain temperature measurements 
both in vitro and in vivo utilising a fully portable temperature measurement setup, which does 
not require alignment of any components. 
Our in vitro results indicated that the measured fluorescence change from the probe, and 
temperature change from the RTD could be approximated as linear over the biologically 
relevant temperature range with high precision. Results were not impacted by systematic errors 
caused by large ambient temperature fluctuations that were known to impede previous probe 
configurations and further in vivo results confirmed this finding. We also demonstrated 
repeated brain temperature measurements using this sensor in awake freely-moving rats and 
showed a good correlation between brain and body temperatures recorded throughout the 
experiment. 
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Musolino, S.T., Schartner, E.P., Hutchinson, M.R. and Salem, A., 2019. Improved method for 
optical fibre temperature probe implantation in brains of free-moving rats. Journal of 
neuroscience methods, 313, pp.24-28. 
Work performed in this paper aimed at increasing the durability, and reusability of the sensor, 
as well as its ease of use by developing an improved optical fibre probe fabrication technique 
utilising conventional microdialysis equipment. This work was a direct extension from the 
original probe development work performed prior to the previous paper. Standard 
microdialysis guide cannulas were used in the revised probe structure to facilitate a simplified 
implantation procedure and allow for the removal of the fibre from the animal post-experiment. 
This was done to permit multiple insertion and removal procedures for each probe as well as 
high throughput animal experiments. The rationale for this method optimization was due to the 
probes’ durability issues both pre-experiment, and post-MDMA administration during periods 
of increased animal movement. Fixing these issues with commercially available equipment 
such as fibreoptic commutators or short indwelling fibre segments commonly used in 
optogenetic applications was not possible for our application due to their incompatibility with 
PM fibre used in the portable configuration. The current study investigated the impacts of these 
improvements to the probe whilst recording MDMA-induced increases in temperature from the 
brains of freely-moving rats. 
Our results indicated that the new probe structure was easily implanted and extremely durable 
both pre-experimentation and during sampling in vivo. Follow-up in vitro experiments 
confirmed the probe was capable for reuse after removal from the animal. The capability for 
probe reusability significantly increased experimental workflow and time and resources lost 
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due to repeated probe fabrication post-experiment. We also showed that rats administered 
MDMA showed pathological increases in brain temperature, which resulted in the deaths of 
two animals. 
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Musolino, S.T., Schartner, E.P., Hutchinson, M.R. and Salem, A., 2019. Minocycline 
attenuates 3,4-methylenedioxymethamphetamine-induced hyperthermia in the rat 
brain. European Journal of Pharmacology, 858, pp. 172495. 
This paper shifts in focus to the first two papers. The previous papers focused mainly on initial 
optical fibre probe proof-of-concept, and further improvements to the original method. The aim 
of the current study was to use this optimised method of brain thermorecording to investigate 
the effects of the tetracycline drug minocycline on MDMA-induced increases in brain 
temperature, and the relationship between MDMA-induced temperature change in the brain 
when compared to the body. The current study compared the brain and body temperature 
changes occurring post-MDMA administration at both normal and high ambient temperature, 
as well as minocycline’s hyperthermia attenuating effects in the brain and body. Concurrent 
measures of HR, and LMA were also undertaken to examine drug effects on these physiological 
parameters, as well as to better understand the physiological and pharmacological mechanisms 
underlying minocycline’s’ attenuation of MDMA-induced hyperthermia. Rationale for this 
investigation was based on lack of previous information regarding minocycline’s 
hyperthermia-attenuating effects in the brain, as well as lack of knowledge regarding MDMA-
induced brain hyperthermia in general. 
Our study indicated that the temperature effects of MDMA occur more rapidly and to a greater 
extent in the brain when compared to the body. Brain temperatures dropped more suddenly and 
to lower levels when compared to body when MDMA was administered at normal ambient 
temperature. A similar trend was also apparent at high ambient temperature with significantly 
faster and more pronounced temperature elevations in the brain when compared to the 
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periphery. These rapid increases in temperature resulted in two fatalities when brain 
temperatures reached ~43 °C. HR and LMA were also significantly elevated post-MDMA. A 
three-day minocycline pretreatment attenuated MDMA-induced hyperthermia in the brain as 
well as in the body, and prevented all fatalities resulting from MDMA administration at high 
ambient temperature. We also found that minocycline attenuated MDMA-induced increases in 
LMA, and lowered baseline HR levels prior to MDMA administration. 
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Chapter 6 – General Discussion 
Portable optical fibre probe development 
The focus of our work concerning fibre optic probe development aimed at optimising optical 
fibre temperature sensor configuration, which required addressing many issues related to its 
long-term stability and in vivo durability. This goal was achieved by using an all-PM optical 
configuration, and altering the probes’ structure we were successful in developing a portable 
optical temperature sensor capable of specific and reliable long-term temperature 
measurements in the brains of freely-moving rats. Continued development of the sensor further 
optimised fabrication and implantation procedures allowing for increased ease of use, lower 
costs, and higher throughput animal experiments. 
Although optical fibre sensors have found increasing use in modern medical applications (Yin 
and Ruffin, 2006), and have been substantially researched and improved upon since the first 
generations of optical fibre sensors were commercialised, they have yet to find the commercial 
success and widespread use that optical fibres have found in other applications, such as 
communications. One possible reason for this is likely associated with the numerous difficulties 
in employing these sensors within in vivo studies as we have demonstrated within our own 
initial developmental work. Despite these difficulties, many sensors have been successfully 
tested in vivo measuring pH (Grant et al., 2001), temperature (Samset et al., 2001), pressure 
(Poeggel et al., 2015), strain (Dziuda et al., 2012), as well as a variety of other parameters. 
However, in many animal studies, these optical fibre sensors have been used to perform in vivo 
measurements in animals under anaesthesia (Grant et al., 2001, O'Hara et al., 2005, Chavko et 
al., 2007, Peterson et al., 1984, Yu et al., 2016). This is likely due to the mechanical strength 
of the fibres being insufficient to withstand strain caused by animal movement (Schena et al., 
2016). As seen in our developmental work, animal movement and fibre coiling can affect 
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optical signal transmission within the probe that can lead to measurement inaccuracies, which 
can be limited using anaesthesia. However, anaesthesia is also known to alter core temperature, 
neuronal activity, and behavioural response in animals (Kiyatkin, 2005, Kiyatkin, 2010), which 
may produce confounding effects on data gathered by the optical sensors used in these studies. 
Similar in vivo studies have reported limitations regarding animals needing to remain tethered 
to fibres post-implantation, with extra care required to prevent damage to fibre tips during long-
term measurements (Cui et al., 2014). Other studies reviewing the current state of optical fibres 
in biomedical studies and the healthcare industry have attributed their lacking use to 
deficiencies in well-designed sensors for their specific applications (Vincent et al., 2014), and 
a lack of standardised protocols capable of producing repeatable and reproducible results in 
vivo (Chiavaioli et al., 2017). In contrast to this, the numerous structural changes made to our 
optical sensor, and the optimisations made to the probe implant and handling procedures have 
minimised the effects of these limitations in our temperature sensing application. The finalised 
probe is durable enough to withstand use in active rats administered MDMA without breakage 
or significant periods of signal loss, and provide stable long-term measurements of brain 
temperature. In addition to this, the improved guide cannula probe housing allows for probe 
separation from the animal post-implant, probe re-use, and repeatable measurements requiring 
only one calibration, while also maintaining the simple implant and handling procedures of 
conventional microdialysis techniques. 
Although there can be many limitations associated with the deployment of optical fibres in 
vivo, we believe that their potential advantages far outweigh the initial drawbacks related to 
their implementation. New optimisations are constantly being made to optical fibre sensors for 
not only traditional sensing parameters such as temperature, strain, and pressure, but also for 
new applications such as chemical sensing (Wang et al., 2016, Schartner et al., 2016) and 
biosensing (Long et al., 2014, Singh and Gupta, 2013, Coscelli et al., 2009). My development 
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and validation of the optical fibre point temperature sensor within a portable system provided 
a suitable means for investigating temperature change within the brain whilst maintaining the 
advantages provided by optical fibre sensing. Future development of this sensor could aid in 
providing a method that enables the multiplexed, real-time in vivo sensing of physical, 
chemical, and biological parameters within one system, which would far exceed capabilities of 
the equivalent conventional temperature monitoring techniques.  
Thermoregulatory effects of MDMA 
The second component of this study successfully applied the portable optical fibre temperature 
sensor to investigate MDMA’s thermoregulatory effects in the brain and the relationnship to 
temperature changes in the body. We showed that MDMA at 10 mg/kg increases brain and 
body temperature when given to male SD rats at high ambient temperature (29 oC). Conversely, 
at normal ambient temperature (22 oC) the same dose of MDMA induced a significant 
hypothermic response. In both cases, these temperature changes occurred more rapidly, and to 
a greater extent in the brain when compared to the body.  
Our results demonstrated contrasting temperature responses to MDMA under differing 
environmental conditions. These findings are synonymous with previous literature showing 
that the magnitude of MDMA-induced hyperthermia is greatly influenced by ambient 
temperature (Gordon et al., 1991, Mechan et al., 2002, Malberg et al., 1996, Malberg and 
Seiden, 1998). The two key physiological mechanisms underlying MDMA-induced 
hyperthermia are increased metabolic rate and increased peripheral vasoconstriction (Brown 
and Kiyatkin, 2004). MDMA-induced increases in metabolism results in increased heat 
production while MDMA-induced peripheral vasoconstriction impairs the body’s ability to 
dissipate this excess heat. This leads to increased heat accumulation in the body and 
hyperthermia. High ambient temperatures are known to significantly increase metabolic rate 
Chapter 6 – General Discussion 
 
Stefan Musolino, PhD Thesis 2019  109 
and heat production in rats compared to lower ambient temperatures (Gordon et al., 1991), thus 
leading to a significantly amplified hyperthermic response (Malberg and Seiden, 1998, Brown 
and Kiyatkin, 2004, Mechan et al., 2002). As mentioned previously, MDMA-induced 
hyperthermia has been linked to the release, and inhibition of uptake of monoamines such as 
5-HT, DA, and NA following MDMA administration (Stone et al., 1986, Gordon et al., 1991, 
Green et al., 2003, Stanley et al., 2007). Extracellular levels of these neurotransmitters are also 
ambient temperature dependent as past studies have shown significant decreases in 
neurotransmitter activity in response to MDMA administered at low ambient temperatures 
(Bowyer et al., 1992) compared to administration at high ambient temperatures (Clausing et 
al., 1996, Tao et al., 2015). Our results support these findings and suggest that modulation of 
physiological and pharmacological actions of MDMA by high ambient temperature greatly 
increases the severity of MDMA-induced hyperthermia in response to a modest dose of 
MDMA. This was further reflected by the death of two of four animals administered MDMA 
at high ambient temperature, with body temperatures in excess of 43 °C. This finding is 
concerning as the accepted LD50 for MDMA administration in the rat is 49 mg/kg (i.p.) 
(Hardman et al., 1973), almost five times higher than the dose used in our studies. In contrast, 
the administration of same-dose MDMA at normal ambient temperature did not result in 
premature death of any animals. These findings have significant implications for instances of 
human drug use as these harmful high-ambient temperature conditions are typical of settings 
where stimulant drugs such as MDMA are taken. Potentiation of drug effects by detrimental 
environmental conditions pose a serious problem to unaware drug users as relatively modest 
doses of MDMA taken under these conditions may result in severe adverse effects and in rare 
cases even death. 
Our results also demonstrate that administration of MDMA at high ambient temperature 
elicited a significant temperature increase in both the brain and the body. However, brain 
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temperatures rose more quickly and to a higher degree compared to the periphery. Striatal 
temperatures were significantly elevated approximately 12 minutes post-MDMA 
administration, compared to 24 minutes in the body. The brain-body temperature differential 
was also significant during peak hyperthermia with brain temperatures approximately 0.6 °C 
higher on average than those in the body. Although current literature surrounding MDMA-
induced hyperthermia in the brain is limited, our results are comparable with previous reports. 
Brain temperatures have been shown to increase faster, and to greater elevations than those in 
the body (+0.4 - 0.8 °C) (Kiyatkin et al., 2002, Brown and Kiyatkin, 2004). These results are 
not surprising as the brain is responsible for 20% of the body’s oxygen consumption and has 
significantly higher metabolic rates compared to the rest of the body (Bélanger et al., 2011). 
Activation of neurons is energy intensive and the majority of this energy is spent re-establishing 
membrane potentials after neurotransmitter release (Richie, 1973). Most of the energy used to 
maintain constant neural activity is eventually transformed into heat (Richie, 1973, Bélanger 
et al., 2011), thus increased neural activity and neurotransmitter release in the brain induced by 
MDMA (Gordon et al., 1991, Mechan et al., 2002, Freezer et al., 2005, Stanley et al., 2007) is 
likely to contribute to increased heat production and eventually hyperthermia. This is relevant 
to humans as core temperature is a key vital sign and is often monitored in a clinical setting, 
however, our results suggest that it does not give an adequate reflection as to the severity of 
MDMA-induced temperature effects in the brain. Although the monitoring of brain 
temperature in humans has undergone great strides in the past few decades, identifying 
differences between brain and core body temperature in patients undergoing neurosurgery 
(Mellergard and Nordström, 1990, Mellergård, 1995, Rossi et al., 2001, Soukup et al., 2002), 
these techniques are impractical in an acute emergency room setting. Additional studies 
performing brain and body temperature measurements in animals, or in humans during 
neurosurgery could aid in developing a formula for extrapolating brain temperature information 
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from core body temperature readings. However, this would require many more neuroscience 
studies adopting brain temperature recording techniques within their protocols before this could 
be achieved. Nevertheless, the increased magnitude of MDMA-induced hyperthermia in the 
brain must be taken into consideration in a clinical setting, and therapeutic interventions should 
ideally exert their cooling effects in the brain accordingly. 
Minocycline’s effects on MDMA-induced hyperthermia 
The primary aim of our work concerning minocycline was to investigate its hyperthermia-
attenuating effects in the brain at high ambient temperature. We also used radiotelemetry to 
further examine the extent of its temperature effects in the periphery. Our results demonstrated 
that a three-day pretreatment with minocycline (50 mg/kg) significantly attenuated MDMA-
induced hyperthermia in both brain and body. MDMA-induced temperature increases in the 
brain and body were attenuated for all time periods following drug administration and average 
peak temperature increases reached only +1.5 °C from baseline, significantly reduced 
compared to saline/MDMA treated groups of over +4 °C. Brain-body temperature differentials 
during MDMA’s peak of action were non-significant, consistent with minocycline’s central 
action. 
There are only a few studies detailing minocycline’s effects in regard to MDMA-induced 
hyperthermia and the protective properties that we have demonstrated are not consistent with 
those reported previously. It is known that an increase in IL-1β concentration, a pro-
inflammatory cytokine and pyrogen, is involved in the development of hyperthermia following 
MDMA administration (Orio et al., 2004, O’Shea et al., 2005). Release of IL-1β is also 
associated with increased activity of nuclear factor kappaB (NF-κB), an inducible transcription 
factor with a key role in regulation of genes involved in inflammatory and immune responses, 
and a contributor to a cyclical mechanism of continued IL-1β  release (Orio et al., 2004, Ahn 
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and Aggarwal, 2005, Nadjar et al., 2005). Minocycline is known to attenuate the increased 
expression of intracellular cysteine protease caspase-1 (Yrjänheikki et al., 1998, Chen et al., 
2000, Mievis et al., 2007), an enzyme which acts to process inactive pro-IL-1β into its mature 
state (Thornberry et al., 1992). It has also been shown to attenuate MDMA-induced NF-κB 
DNA binding in a region specific manner (Orio et al., 2010). In addition to this, minocycline 
region-specifically attenuates loss of 5-HTT related to reductions in IL-1β and NF-κB 
signalling in these regions (Orio et al., 2010), and attenuates 5-HT and DA loss, as well as 
microglial activation in response to MDMA (Zhang et al., 2006). Although monoamine release, 
microglial activation, and subsequent release of pro-inflammatory cytokines are known to play 
a role in development of hyperthermia in response to MDMA (Stone et al., 1986, Gordon et 
al., 1991, Malberg and Seiden, 1998, Stanley et al., 2007, Orio et al., 2004, O’Shea et al., 2005), 
previous studies show that minocycline’s action within monoamine and neuroinflammatory 
systems does not correspond with attenuation of acute hyperthermia in the body (Zhang et al., 
2006, Orio et al., 2010). In contrast to these findings, prior work in our lab showed that a three-
day pretreatment with minocycline (50 mg/kg) was sufficient to attenuate MDMA-induced 
hyperthermia at normal ambient temperature (Anderson et al., 2011). Our results are consistent 
with this and go one step further to demonstrate that minocycline is also effective in attenuating 
the exacerbated MDMA-induced hyperthermic response in both the brain and body at high 
ambient temperature. Discrepancies between results from our lab and those of others may have 
resulted, at least in part, from methodological differences, including a higher dose of MDMA, 
a lower dose of minocycline, and differences in animal species and strain (Zhang et al., 2006, 
Orio et al., 2010). However, they might best be explained by the reduced minocycline 
pretreatment time period used, one to two days, compared to our three-day pretreatment period. 
We found that a three-day minocycline pretreatment period not only attenuates modest (10 
mg/kg, i.p.) MDMA-induced hyperthermia at normal ambient temperature, but also attenuates 
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exacerbated and possibly deadly hyperthermia at high ambient temperature. These results 
highlight the time-dependent nature of minocycline’s hyperthermia-attenuating mechanisms of 
action. Our results may also provide some insight into actions of minocycline within different 
regions of the brain. There is known heterogeneity in the release of IL-1β in the brain in 
response to MDMA, specifically in the hypothalamus (Tringali et al., 1996, Tringali et al., 
1997, Lindberg et al., 2004, O’Shea et al., 2005). Release of IL-1β is thought to be a 
consequence of MDMA-induced hyperthermia rather than its cause, based on its delayed peak 
concentrations compared to the rapid onset of hyperthermia, and the absence of its release when 
hyperthermia is abolished (Orio et al., 2004, O’Shea et al., 2005). A reduction in MDMA-
induced IL-1β release by minocycline in brain areas such as the midbrain (Anderson, 
unpublished data) and frontal cortex (Orio et al., 2010) could reflect increased hypothermic 
action in these brain areas, possibly through the attenuation of acute monoamine release. This 
is in contrast to the hypothalamus where insignificant decreases in IL-1β signalling in response 
to shorter minocycline pretreatment periods, and no attenuation of hyperthermia has been 
reported (Orio et al., 2010). This suggests a three-day minocycline pretreatment period is 
required to achieve significant attenuation of acute MDMA-induced increases in extracellular 
monoamines, and subsequent release of IL-1β in the hypothalamus that plays a key role in 
development of hyperthermia in the brain and body. This idea is further supported by the fact 
that the hypothalamus is known to possess a readily available pool of mature IL-1β available 
for release, that originates in neurons (Lindberg et al., 2004), with release mediated by 
dopamine (Tringali et al., 1996, Tringali et al., 1997). However, further studies examining 
multiple brain regions, and using both microdialysis and IL-1β assays would be required to test 
this hypothesis. 
Hyperthermia is known to exacerbate long-term MDMA-induced 5-HT and DA neurotoxicity 
(Gordon et al., 1991, Broening et al., 1995, Malberg and Seiden, 1998, Brown and Kiyatkin, 
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2004, O'Shea et al., 2005) thus, our results support the hypothesis that minocycline’s 
neuroprotective effects are linked to its ability to attenuate acute hyperthermia. Attenuation of 
pathological brain and body tissue over-heating by minocycline was shown to prevent 
premature hyperthermic death in all animals administered MDMA. This survival rate is 
significant considering the increased danger MDMA poses when taken under deleterious high-
ambient temperature conditions (Brown and Kiyatkin, 2004). This also supports the hypothesis 
that drugs acting centrally to prevent brain hyperthermia such as minocycline are more 
effective in attenuating MDMA-induced hyperthermia compared to those acting in the 
periphery as previously demonstrated (Kiyatkin et al., 2016). These findings are relevant 
clinically considering the limited therapeutic techniques currently in use for treatment of acute 
drug-induced hyperthermia in humans, none of which involve pharmacotherapies that exhibit 
direct cooling effects in the brain (Kiyatkin et al., 2016). Considering this, future 
pharmacotherapies and clinical techniques aimed at alleviating the adverse temperature effects 
of MDMA should ideally have action within the brain where we have demonstrated these 
effects are most severe. 
MDMA-induced Heart Rate and Locomotor Activity changes 
In addition to brain and body temperature, HR and LMA were measured during all in vivo 
MDMA and minocycline experiments. Most data were consistent with existing literature 
reporting the individual effects of these drugs on HR and LMA (Jaehne et al., 2008, Liechti 
and Vollenweider, 2000, Orio et al., 2010, Badon et al., 2002, Bankson and Cunningham, 2001, 
Baumann et al., 2008, Zhang et al., 2007). However, there is no literature currently available 
that investigates the cardiovascular and behavioural effects of minocycline in the context of 
MDMA-induced hyperthermia. Inclusion of these measures in our studies gave added insight 
into potential pharmacological mechanisms underlying the attenuation of MDMA-induced 
hyperthermia by minocycline that warrants further discussion.  
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In our third paper, we demonstrated that acute MDMA administration significantly increased 
HR at high ambient temperature, a result consistent with existing literature (Dafters, 1994, 
Bexis and Docherty, 2006, Green et al., 2003, Jaehne et al., 2008). Delayed increases in HR 
were also observed at normal ambient temperature post-MDMA, however, these were 
significantly reduced compared to high ambient temperature administration. Cardiovascular 
physiology is important in mammals when adapting to changes in ambient temperature (Jaehne 
et al., 2008). While core temperatures are being maintained, cardiovascular changes in response 
to cold ambient temperatures are closely related to mechanisms of heat production in rats, 
which increase in parallel with HR (Chambers et al., 2000). Similarly, in non-human primates, 
disruption of the pre-optic anterior hypothalamus by direct cooling has been linked to increases 
in HR and core temperature, while direct warming has been linked to lower HR and decreases 
in core temperature (Morishima and Gale, 1972). Changes in HR and other cardiovascular 
parameters may therefore give an indirect indication of heat production and disrupted 
autonomic thermoregulation. This suggests that higher HR observed in animals treated at high 
ambient temperature could be related to their higher brain and core body temperatures. 
However, reduced but significant HR increases also occurred in rats exhibiting brain and body 
hypothermia when administered MDMA at normal ambient temperature, which does not fit 
with this hypothesis (Jaehne et al., 2008). This suggests that MDMA’s effects on HR may occur 
independently from its effects on brain and body temperatures. 
The effect of MDMA on cardiovascular parameters such as HR and blood pressure are 
comparable to other sympathomimetic agents such as amphetamine (O'Cain et al., 2000) and 
cocaine (Branch and Knuepfer, 1992) whose mechanisms of cardiac stimulation involve both 
central and peripheral sympathetic components. (Schindler, 1996). Existing literature indicates 
that the adrenergic system is the primary mediator underlying the cardiovascular effects of 
MDMA. Administration of β-adrenoreceptor antagonists have been shown to block MDMA-
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induced increases in HR (Hysek et al., 2010, Schindler et al., 2014), and both α1- and α2-
adrenoreceptor antagonists are known to reduce the duration of MDMAs cardiovascular effects 
(O'Cain et al., 2000, Vandeputte and Docherty, 2002) and in some cases completely reverse 
them (McDaid and Docherty, 2001). NA uptake blockers are also known to reduce blood 
pressure and HR elevations following MDMA administration in humans, indicating that the 
NA transporter is involved in this mechanism (Hysek et al., 2011). In addition to this, central 
monoamine systems are known to contribute to the cardiovascular effects of MDMA (Liechti 
and Vollenweider, 2000, Liechti et al., 2001). Agonist activity of MDMA at 5-HT2 receptors 
is known to contribute to cardiovascular stimulation (McDaid and Docherty, 2001) while 
inhibition of 5-HT uptake by selective serotonin reuptake inhibitors (SSRI) attenuates this 
stimulation induced by MDMA (Liechti and Vollenweider, 2000). Dopamine receptor 
blockade is known to reduce the subjective effects of MDMA in humans, however this does 
not alter the drugs’ cardiovascular effects (Liechti et al., 2000a, Liechti et al., 2001). Pro-
inflammatory cytokine release in the CNS is also known to modify sympathetic neuronal 
outflow, which plays a key role in the regulation of cardiovascular function (Kannan et al., 
1996, Kimura et al., 1993, Ufnal et al., 2005, Liechti and Vollenweider, 2000). As mentioned 
previously, minocycline is known to attenuate MDMA-induced 5-HT neurotoxicity (Zhang et 
al., 2006, Orio et al., 2010), and the maturation and release of pro-inflammatory cytokines 
(Yrjänheikki et al., 1998, Chen et al., 2000). Furthermore, it has been shown to offer cardiac 
protection via reduction in markers of oxidative stress (Salameh et al., 2015), which are known 
to be increased following MDMA administration (Song et al., 2010). Although not quantified 
in our studies, it is likely that minocycline’s inhibition of MDMA-induced microglial activation 
and pro-inflammatory cytokine release, in conjunction with its direct reduction in MDMA-
induced central monoamine release contributed to its hypothermic effects in the brain and body, 
reflected in our study by the reduction in cardiac stimulation following acute MDMA 
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administration. These inhibitory cardiovascular effects may also indicate that minocycline also 
has a mechanism of action at peripheral α- and β-adrenoreceptors, as well as activity at the NA 
transporter that are involved in regulation of cardiovascular activity. Furthermore, the reduction 
of baseline HR pre-MDMA administration by minocycline may indicate that it reduces baseline 
monoamine activity levels in the brain, and may also directly accumulate in cardiac tissue to 
reduce cardiac stimulation (Romero-Perez et al., 2008). However, further ligand-receptor 
binding studies would be required to test these hypotheses. 
In addition to its cardiovascular effects, our results show that MDMA administration causes 
significant increases in LMA that were also impacted by minocycline. LMA was significantly 
elevated for approximately 2 h post-MDMA administration at both normal and high ambient 
temperatures before activity levels decreased nearing the end of the experiment. The increase 
in activity post-MDMA agrees with previous literature demonstrating MDMA-induced 
increases in locomotion (Bankson and Cunningham, 2001, Bankson and Cunningham, 2002, 
Baumann et al., 2008). Like MDMA’s effects on HR, these changes in LMA occurred 
independently from increases in brain and body temperature. These results are in-line with 
previous literature reporting that abolishment of hyperthermia by low ambient temperatures 
had no effect on MDMA-induced hyperkinesis (Dafters, 1994). This dissociation indicates that 
MDMA-induced heat production via hyperlocomotion is not a major factor determining the 
magnitude of the hyperthermic response. 
Increased locomotion induced by MDMA is thought to primarily involve an increase in 
dopaminergic activity (Baumann et al., 2008). However, drug-induced hyperlocomotion is also 
accompanied by behavioural features of serotonin syndrome (Spanos and Yamamoto, 1989, 
Colado et al., 1993), and drug actions at both the 5-HTT and 5-HT receptors have also been 
implicated in this response (Bankson and Cunningham, 2001, Bankson and Cunningham, 
2002). Furthermore, glutaminergic system activation is known to produce hyperlocomotion, 
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and the inhibitory activity of minocycline at glutamate receptors has been demonstrated to 
reduce baseline LMA as well as amphetamine-induced increases in LMA (González et al., 
2007, Zhang et al., 2007, Tikka and Koistinaho, 2001). Our results demonstrate that 
pretreatment with minocycline significantly attenuated MDMA-induced increases in 
locomotion at high ambient temperature. Although not quantified in our studies, our results 
support the hypothesis that minocycline’s attenuation of MDMA-induced brain and body 
hyperthermia involves both the direct and indirect inhibition of acute DA (Zhang et al., 2007) 
and 5-HT release (Orio et al., 2010), as well as the reversal MDMA-induced monoamine 
reuptake impairment, as explained by the drugs attenuation of MDMA-induced increases in 
LMA. However, future studies examining acute neurotransmitter and pro-inflammatory 
cytokine release, metabolism, and reuptake would be required to confirm these hypothesis.  
Future directions  
The most important aspect that should be expanded upon in the future is the combination and 
multiplexing of this temperature probe with other optical sensors and sensing equipment. One 
of the main advantages of optical fibre sensors for biomedical monitoring applications in the 
CNS is their ability to provide for multiplexed sensing using one implanted probe.  This limits 
potential stress or tissue damage that would accompany implantation of multiple different 
sensors for monitoring of multiple parameters. Due to the relatively small size of our fibre-tip 
sensor, it can be easily combined with existing sensors, or multiplexed with other compatible 
optical sensors. For example, we have already successfully demonstrated successful 
multiplexing of this sensor with an optical coherence tomography imaging sensor for 
simultaneous brain temperature sensing and structural imaging (Li et al., 2018) (see Appendix 
1). Another promising option for multiplexing would be the previously demonstrated optical 
fibre immunosensor for localized detection of IL-1β (Zhang et al., 2019). Ex vivo results using 
this sensor demonstrated a significant correlation with commercial IL-1β ELISA kits, and 
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successfully carried out localized measurement of IL-1β in anesthetized rats. The combination 
of these two sensors in future studies could allow simultaneous monitoring of MDMA-induced 
brain temperature change, and IL-1β release in vivo without the need for conventional and time-
consuming IL-1β immunoassays. The combination of optical fibre sensors with other 
neurochemical assays such as microdialysis, as well as other recording techniques such as 
radiotelemetry monitoring could lead to a powerful armamentarium of approaches that provide 
a comprehensive view of the physiological and pharmacological effects of acute MDMA 
administration, and to assess pharmacological interventions aimed at attenuating the resulting 
hyperthermic response. 
Ideally future MDMA studies using this temperature sensor would include examining a variety 
of other factors to further the results and better understand MDMA-induced hyperthermia. One 
important aspect of this thesis to build on includes examination of MDMA co-administration 
with other drugs that may prevent the adverse thermoregulatory effects of MDMA. This 
includes any drug with action on central 5-HT, DA, and NA systems, as well as noradrenergic 
transmission in the periphery such as receptor agonists, antagonists, selective reuptake 
inhibitors, transporter blockers, and drugs that prevent neurotransmitter breakdown such as 
MAO inhibitors. Examination of drugs with central anti-inflammatory properties similar to 
minocycline should also be included in this investigation. Previous studies with these types of 
drugs have demonstrated attenuation of hyperthermia owing to modulation of neurotransmitter 
activity (Malberg et al., 1996, Mechan et al., 2002, Blessing et al., 2003) and 
neuroinflammation (Porceddu et al., 2016) following MDMA administration. Investigation of 
these drugs would lead to a more complete understanding of the mechanisms underlying 
MDMA-induced hyperthermia, and the priority pathways in which future pharmacological 
interventions should target to achieve adequate attenuation of this dangerous clinical symptom 
in an acute setting. 
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Other options for furthering results presented in this thesis include examining drug 
administration schedules, conditions of drug administration, and MDMA administration with 
other stimulant drugs. For example, in the last paper, we attempted to simulate conditions 
typical of human drug administration by administering single-dose MDMA at high ambient 
temperature and investigating the therapeutic effects of minocycline under these deleterious 
environmental conditions. However, this one change to conditions under which the drug was 
administered may be too simplistic when attempting to simulate human drug use. Other factors 
such as social interaction, water consumption, repeated dosing, and co-administration with 
other drugs are also typical of human drug use and have been shown to further exacerbate 
MDMA-induced hyperthermia and contribute to the drug’s adverse effects (Dafters, 1995, 
Brown and Kiyatkin, 2004, Stanley et al., 2007). Inclusion of these factors during future in vivo 
sampling would yield results more relatable to human use. The efficacy of potential 
pharmacological interventions for attenuation of acute MDMA-induced hyperthermia in 
humans could then be better evaluated. 
Conclusions 
I have demonstrated an optical fibre point temperature sensor capable of performing in vivo 
temperature measurements in the brains of freely-moving, MDMA-treated rats. The improved 
temperature probe utilised equipment commonly found in other neurochemical assays to enable 
ease of use and handling, and to help facilitate its translation into medical laboratories where 
these optical sensors could provide many advantages over current monitoring technologies. 
Using this sensor, I demonstrated that, at high ambient temperature, MDMA induced a 
significantly more rapid and intense hyperthermic response in the brain when compared to the 
body, and was much more lethal than expected under these conditions based on its accepted 
LD50. I subsequently demonstrated that pretreatment of animals with the tetracycline drug 
minocycline was effective in attenuating MDMA-induced hyperthermia in both the brain and 
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body, and prevented the fatalities caused by administration of MDMA at high ambient 
temperature. Minocycline’s attenuating effects on MDMA-induced increases in HR and LMA 
provided some insight into its mechanisms of actions within neuronal and neuroinflammatory 
pathways in the brain, however subsequent studies should employ further quantification of 
monoamine levels and neuroinflammation to validate these findings. The current state of 
research surrounding MDMA makes it clear that pharmacology of the hyperthermic response 
is not fully understood. Further work is needed regarding the thermoregulatory effects of 
MDMA in the brain, and the central effects of potential therapeutics in order to better 
understand mechanisms underlying acute hyperthermia, and the best pathways to target for the 
effective treatment of MDMA-induced hyperthermia. Continued advancement of optical fibre 
sensing technology for physical, chemical, and biological monitoring in vivo is likely to provide 
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